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The Surgical Infection Society Guidelines on
Antimicrobial Therapy for Intra-Abdominal Infections:
Evidence for the Recommendations
JOHN E. MAZUSKI, 1 ROBERT G. SAWYER,2 AVERY B. NATHENS,3 JOSEPH T. DIPIRO,4
MOSHE SCHEIN,5 KENNETH A. KUDSK,6 and CHARLES YOWLER7 FOR THE
THERAPEUTIC AGENTS COMMITTEE OF THE SURGICAL INFECTION SOCIETY

ABSTRACT
Revised guidelines for the use of antimicrobial therapy in patients with intra-abdominal infections were recently developed by the Therapeutic Agents Committee of the Surgical Infection Society (Mazuski et al., Surg Infect 2002;3:161–173). These were based, insofar as possible, on evidence published over the past decade. The objective of this document is to
describe the process by which the Committee identified and reviewed the published literature utilized to develop the recommendations and to summarize the results of those reviews.
English-language articles published between 1990 and 2000 related to antimicrobial therapy
for intra-abdominal infections were identified by a systematic MEDLINE search and an examination of references included in recent review articles. If current literature with regard to
a specific issue was lacking, relevant articles published prior to 1990 were identified. All
prospective randomized controlled trials, as well as other articles selected by the Committee,
were evaluated individually and collectively. Data with regard to patient numbers, types of
infections, and results of interventions were abstracted. Studies were categorized according
to their design, and all included trials were graded according to quality. On the basis of this
evidence, the Committee formulated recommendations for antimicrobial therapy for intra-abdominal infections and graded those recommendations. After receiving comments from invited reviewers and the general membership of the Society, the guidelines were finalized and
submitted to the Council of the Surgical Infection Society for approval. The final recommendations related to the selection of patients needing therapeutic antimicrobials, acceptable
antimicrobial regimens, duration of antimicrobial use, and the identification and treatment
of higher-risk patients. Although numerous publications pertaining to these topics were
identified, but nearly all of the prospective randomized controlled trials represented comparisons of different antimicrobial regimens for the treatment of intra-abdominal infections.
A few prospective trials evaluated the need for therapeutic antimicrobial therapy in patients
with peritoneal contamination following abdominal trauma. The quality of these prospective
trials was highly variable. Many did not limit enrollment to patients with complicated intraFrom the Departments of Surgery, Saint Louis University School of Medicine, St. Louis, MO,1 University of Virginia, Charlottesville, VA,2 University of Washington, Seattle, WA,3 Bronx Lebanon Hospital Center, Bronx, NY, 5 University of Tennessee, Memphis, TN,6 Case Western Reserve University, Cleveland, OH,7 and the College of Pharmacy, University of Georgia, and Department of Surgery, Medical College of Georgia, Augusta, GA4
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abdominal infections, lacked blinding of treatment assignment, did not provide a complete
description of the criteria used to determine therapeutic success or failure, failed to identify
the reasons why patients were excluded from analysis, or did not include an intention-to-treat
analysis. For many issues, no prospective randomized controlled trials were encountered, and
guidelines had to be formulated using evidence from studies with historical controls or uncontrolled data, or on the basis of expert opinion.

INTRODUCTION

I

1992, the Antimicrobial Agents Committee
(now the Therapeutic Agents Committee) of
the Surgical Infection Society (SIS) published
guidelines for the use of antimicrobial agents
in patients with intra-abdominal infections [1].
These guidelines defined the types of infections
that required antimicrobial therapy, characterized the bacteria likely to be involved in those
infections, described the general principles for
the use of antimicrobials, and recommended
specific antimicrobial agents or combination
regimens which were considered appropriate
for treatment. The Therapeutic Agents Committee of the SIS has recently updated the original guidelines published in 1992, primarily using literature published since 1990 [2]. These
revised guidelines represent an extension, but
not a replacement of the original guidelines developed by Bohnen et al. [1].
In undertaking this revision, the Committee
set as an additional goal the formal categorization of its recommendations according to
current principles of evidence-based medicine.
Although there is no universally accepted system for describing clinical evidence or recommendations [3], most authors employ terminology similar to that originally developed by
the Canadian Task Force on the Periodic Health
Evaluation [4]. Using this methodology, the
published studies used to create recommendations are first categorized according to study
design and quality, and then, in turn, the recommendations developed from these studies
are graded according to the strength of evidence behind them.
In this article, we will first describe the
processes by which the Committee selected and
evaluated the literature relevant to these guidelines, and integrated these data to formulate the
N

recommendations regarding antimicrobial
therapy for patients with intra-abdominal infections. Then, the actual evidence used in developing the guidelines will be detailed separately with regard to the four major topics
reviewed: (1) the selection of patients requiring
therapeutic antimicrobials; (2) the duration of
antimicrobial therapy; (3) appropriate antimicrobial regimens for treatment of patients with
intra-abdominal infections; and (4) the identification and treatment of higher-risk patients
for whom initial therapy of their infections is
likely to fail.

GUIDELINE DEVELOPMENT
The initial impetus for the development of
these revised guidelines came at the meeting of
the Therapeutic Agents Committee in May
2000, following a directive from the Council of
the SIS that the Committee undertake a formalized process of guideline development and
review. The Committee proposed that a high
priority be given to revising the previous position paper of the Society on the use of antimicrobial therapy for patients with intra-abdominal infections, since this document had not
been revisited in nearly ten years, and was an
issue of importance to the membership of the
Society at large. The proposal to revise these
guidelines was formally accepted by the Council in October 2000, with the Therapeutic
Agents Committee directed to serve as the expert panel for this revision.
The initial deliberations of the Committee focused on the approach to be used in revising
the previous guidelines. Over the past decade,
the “science” of guideline development has undergone considerable evolution, and many organizations have produced guidelines related
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to clinical issues. Among surgical organizations, the Eastern Association for the Surgery
of Trauma (EAST) has been at the forefront in
developing guidelines for the treatment of patients with surgical problems. Their approach
to guideline development has been described
in detail [5]. The Committee therefore selected
this approach as its model for the preparation
of these revised guidelines. The steps recommended by the EAST in guideline development
are outlined in Table 1.
Scope of the guidelines
The Committee first sought to define the
types of patients with intra-abdominal infections that would be covered by these guidelines, and then to identify specific questions to
be addressed. In general, the Committee chose
to restrict its focus to surgical patients with intra-abdominal infections, that is, those generally described as secondary or tertiary peritonitis, or intra-abdominal abscesses. Patients
who would not be covered by these guidelines
included those with primary peritonitis and
infections associated with indwelling intraabdominal catheters, and those with infections
related to primary gynecological or genitourinary disorders. Patients with localized infections of an abdominal organ for which no primary source control procedure was performed,
such as patients with acute diverticulitis or
cholecystitis treated non-operatively, would
also not be covered by the proposed recommendations. Thus, these guidelines would apply to patients described as having complicated
TABLE 1. DEVELOPME NT OF CLINICAL
PRACTICE GUIDELINES
Step
1
2
3
4
5
6
7
8
9
10

Procedure
Topic selection
Selection of a panel
Clarification of purpose and scope of the
guidelines
Listing of goals and specification of questions
Assessment (grading) of scientific evidence
Establishing the recommendations
Drafting and validation of the document
Presentation
Implementation
Validation

Adapted from Pasquale [5].
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intra-abdominal infections, that is, those requiring a surgical or radiologically guided procedure for control of the infection [6]. These restrictions are quite similar to those used
previously by Bohnen et al. [1].
In the initial discussions, the Committee also
decided not to attempt a complete revision of
the previous guidelines of Bohnen et al. [1].
Many of their descriptions, such as those related to the pathogenesis and microbiology of
intra-abdominal infections, were still up to date
and did not need revising. Instead, the Committee chose to focus on several treatment-related issues that had engendered discussion
both in the published literature as well as at Society meetings during the past decade. Each issue was to be reviewed initially by a two- or
three-member working group of the Committee, and then by the Committee as a whole. The
issues and questions that were selected for discussion fell into four general areas:
Patient selection. Which patients should be
treated with antimicrobials for intra-abdominal
infections? What distinguishes intra-abdominal contamination from an established intra-abdominal infection? Are prolonged courses of
antimicrobials warranted in patients who have
contamination only? What constitutes prophylactic, as opposed to therapeutic, use of antimicrobials for intra-abdominal infections?
Duration of antimicrobial therapy. What is the
optimal duration of antimicrobial therapy for
patients with intra-abdominal infections? Can
this be specified based on the type of intra-abdominal infection? Should clinical symptoms
and signs be used to guide duration of antimicrobial therapy?
Recommended antimicrobial regimens. Which
antimicrobial regimens can be recommended
for the treatment of patients with intra-abdominal infections? Are any of these regimens
of greater or lesser efficacy? Can oral antimicrobials be utilized in patients with intra-abdominal infections? How should aminoglycosides be utilized in these patients?
Identification and treatment of the higher risk patient. What risk factors identify patients likely
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to experience failure of initial therapy? Can the
antimicrobial regimen be intensified in such
patients to decrease the risk of failure? Should
higher–risk patients be treated empirically for
enterococcal or fungal organisms? How should
patients with tertiary peritonitis be treated?
Selection of the literature for review
In order to obtain the best evidence with
which to address these questions, the Committee undertook a systematic search for all English-language articles on the use of antimicrobials for intra-abdominal infections published
between 1990 and 2000. The 1990 limit was selected because the relevant literature up to 1990
had been available to the authors of the previous guidelines. The MEDLINE database was
searched using multiple strategies, in which the
names of specific antimicrobials or more general descriptors (e.g., cephalosporins) were
paired with words and phrases indicating an
intra-abdominal infection (e.g., peritonitis, intra-abdominal abscess, appendicitis). This initial search included studies that were in the
MEDLINE database as of December 4, 2000.
At the outset, one goal of the Committee was
to develop a database of all prospective randomized controlled trials published during this
time period that related to the use of antimicrobial therapy for the treatment of intra-abdominal infections. These publications were
believed to provide the best evidence for potential guidelines. Therefore, all abstracts obtained from this initial search strategy were
screened in an effort to identify any publication that might feature this trial design. To uncover additional prospective randomized controlled trials missed by this screening process,
the references of a number of authoritative review articles discussing treatment of intra-abdominal infections [7–19] were also examined.
A search of the Cochrane Database of Systematic
Reviews [20] was also performed, but this failed
to identify additional relevant publications.
All articles identified by this initial screening
process then received a preliminary review.
Studies that were not prospective randomized
controlled trials were excluded from the database. However, those publications could still be
used for the development of specific recom-
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mendations if an individual working group believed that the study contained information
relevant to the specific topic. In addition,
prospective trials that examined prophylactic,
but not therapeutic, use of antimicrobials, administered to patients who did not have established intra-abdominal infections were also
eliminated from further consideration.
All remaining prospective randomized controlled trials were then reviewed by at least one
member of the Committee to determine their
suitability for inclusion in the database. Studies could be excluded from further consideration for several reasons established by the
Committee. The decision to exclude any given
prospective trial had to be confirmed by a consensus of the Committee as a whole. A few reports were excluded because they were found
to be duplicate publications of the same trial.
Under these circumstances, the publication that
more thoroughly described the trial was included in the database. In addition, some trials
enrolled patients with indications for antimicrobial use other than intra-abdominal infections. These other indications included pneumonia, bacteremia, and soft tissue infections.
Generally, the Committee utilized such trials
only if the clinical efficacy in patients with intra-abdominal infections was described separately from the overall group of patients, and
there were at least 30 evaluable patients with
intra-abdominal infections for whom data were
available. A few studies permitted administration of additional antimicrobials on the basis of
physician discretion, without any clear criteria
for their use being specified in the protocol.
These studies were excluded from the database
if the final efficacy determination was obscured
by the inclusion of such patients. Finally, some
trials enrolled patients who did not undergo
operative therapy of their intra-abdominal infections, and many studies included patients
who did not need prolonged antimicrobial
therapy for established infections, according to
the previous criteria of Bohnen et al. [1] and the
Infectious Disease Society of America (IDSA)
guidelines [6]. Patients in this latter category
included those with simple appendicitis or
cholecystitis, and those with recent traumatic
intestinal perforations or gastroduodenal perforations. Ultimately, the Committee chose to
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include most of these studies in the database,
as long as it appeared that the majority of
evaluable patients had positive peritoneal cultures or diagnoses of complicated intra-abdominal infections requiring therapeutic antimicrobial therapy. However, studies in which
most or all patients could have been treated
with short-term antimicrobial therapy were excluded.
Not surprisingly, many facets of antimicrobial therapy for intra-abdominal infections
were not addressed by prospective randomized controlled trials. Therefore, other studies
that appeared relevant to the development of
these guidelines were also selected from the
body of literature identified during this screening process. Priority for review was given to
epidemiological studies and investigations that
utilized some type of controlled design, although articles expressing the opinions of experts in the field were also collected. The decisions to select additional studies for review was
left to the working groups developing those areas of the guidelines, and ultimately approved
by the Committee as a whole.
For some topics, there was a paucity of evidence published after 1990. Therefore, the individual working groups identified prospective randomized controlled trials and other
studies published prior to 1990 that could be
used to supplement the data obtained from
later investigations. The prospective trials were
included in the database, but a formal, systematic search to identify all such studies published prior to 1990 was not performed.
Evaluation of the evidence
The prospective randomized controlled trials selected for inclusion in the database, and
all other studies judged to be relevant to the
development of the guidelines were reviewed
fully by at least one, and usually two members
of the Committee. Details were abstracted with
regard to the specific topic investigated, the
study design, the types of patients entered and
excluded from the study, and the results of the
treatment interventions. The study design was
classified using the nomenclature outlined by
the EAST [5], and supplemented by descriptions utilized by the American Society for Par-
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enteral and Enteral Nutrition [21] (Table 2). Essentially, Class I evidence was that obtained
from prospective randomized controlled trials
or meta-analyses of those trials, Class II evidence was that obtained from other prospective and retrospective controlled studies containing clearly reliable data, and Class III
evidence was that obtained from uncontrolled
studies, case reports, and expert opinion.
All prospective randomized controlled trials
were further graded for quality using the system devised by Jadad et al. [22] (Table 3). This
assessment assigns a quality score of 0–5 based
on the adequacy of randomization, blinding,
and description of patients excluded from the
study. Reproducibility of the quality ratings
was determined by having second members of
the Committee, blinded to the first reviewers’
scores, grade most studies. Replicate quality
scores were nearly always within one point of
each other, and no major discrepancies were
identified. Minor discrepancies between the reviewers were resolved between the individual
Committee members. Since no generally accepted system exists for assessing the quality
of Class II and Class III evidence, these studies
were not graded objectively.
The quality scores determined from these reviews proved to be quite low. Only about 20%
of the trials received a score of 4 or 5; an additional 20% received a score of 3. The median
quality score for all prospective trials was less
than 2.
Among the individual components of the
quality scores, randomization appeared to be
adequate in nearly all the studies, and most trials were given 1 or 2 points toward the overall
quality score. However, fewer than 30% of the
trials were given any points for blinding, since
most were not designed as double-blind trials.
There were descriptions in some publications
of attempts to obtain blinded assessments of
outcome even though the study was designed
as an open-label trial. Generally, these trials
still did not meet the criteria specified by Jadad
et al. [22] to ensure that they were free from
bias.
The final point of the quality rating is determined by how the investigators have described
patients excluded from the trial after randomization. Both the reasons for exclusions, and the
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TABLE 2.

CLASSIFICATION

Class
I
II
III

OF

EVIDENCE

Evidence
Prospective randomized controlled trials or meta-analyses of such trials.
Prospective studies without randomization or other studies in which data were collected
prospectively, and retrospective analyses based on clearly reliable data. These include
observational studies, cohort studies, prevalence studies, and retrospective case control studies.
Uncontrolled studies using retrospective data, such as clinical series or case reviews, and expert
opinion.

Adapted from Pasquale [5] and Wolfe and Mathiesen [21].

numbers of patients excluded for each reason
need to be detailed. The Committee identified
this as a particular area of concern. Fully onethird of the publications provided an inadequate description of excluded patients. However, there were problems even among the
studies that received credit for providing the
necessary information. It became apparent that
the criteria cited by the various investigators
for excluding patients, that is, defining the clinically evaluable population, varied widely.
Some of these criteria seemed quite arbitrary.
In some trials, patients were excluded automatically if they were found subsequently to
have a resistant organism isolated at the time
of operative intervention, regardless of the results of initial empiric antimicrobial therapy.
Others excluded patients who suffered adverse
reactions to study drugs, even if they were
switched to different antimicrobial agents because of the adverse reaction. In addition, some
studies excluded patients who developed nosocomial infections outside of the abdominal cavity that required subsequent antimicrobial therapy. Although the final outcome in some of
these patients is truly indeterminate, both the
IDSA [6] and the SIS [23] guidelines for the design of these antimicrobial trials indicate that
TABLE 3. QUALITY SCORING

OF

most of these patients can be considered evaluable, as long as success or failure of the therapy of the intra-abdominal infection is apparent at the time treatment of the nosocomial
infection is initiated.
Many studies, as alluded to above, included
patients in the final analysis who should have
been excluded, because they did not have complicated intra-abdominal infections requiring
antimicrobial therapy for greater than 24 h. Examples of such patients included those whose
infections had not been confirmed with positive peritoneal cultures, those who had diagnoses not requiring prolonged antimicrobial
therapy, such as non-perforated appendicitis,
and those who had conditions such as recent
gastroduodenal perforation suggestive of intraabdominal contamination but not infection. In
addition, a few studies included limited numbers of patients with gynecological, perirectal,
or abdominal wound infections, or patients
who were treated non-operatively for an intraabdominal process such as acute diverticulitis.
Unfortunately, the inclusions of such patients
in the clinically evaluable populations limit the
usefulness of these trials for determining optimal antimicrobial therapy of patients with
complicated intra-abdominal infections.

PROSPECTIVE RANDOMIZED CONTROLLED TRIALS

Randomization: Score one point if the study was described as randomized. Add one additional point if the
method of randomization was described, and was appropriate (e.g., random number table, computer-generated
list). Subtract one point if the method of randomization was inappropriate (e.g., alternate allocation, date of birth,
hospital number).
Double blinding: Score one point if the study was described as double blind. Add one additional point if the
method of double blinding was described and was appropriate (e.g., identical placebo, active placebo, dummy).
Subtract one point if the method of blinding was inappropriate (e.g., no double dummy for comparison of an oral
versus an injectable medication).
Withdrawals and dropouts: Score one point if the reasons why randomized patients were withdrawn from
analysis were described, and the numbers of patients withdrawn for each reason were specified.
Adapted from Jadad et al. [22].
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In reviewing all the evidence, the Committee attempted to apply a common descriptor of
outcome to the data obtained from prospective
trials. Most investigators reported a clinical
success or clinical failure rate in evaluable patients. The Committee generally chose to use
the investigators’ reported clinical success
rates, or recalculated clinical success rates
when necessary, as its common measure of outcome.
For a number of reasons, however, the reported clinical success rates were not readily
comparable across the various studies. As discussed above, investigators used different criteria to exclude patients from the final analysis, which changes the denominator used to
calculate success rates. Of perhaps greater importance, investigators utilized different criteria to describe clinical successes and failures,
which affects the numerator used in these calculations. Unfortunately, in some publications,
the authors failed to specify exactly the criteria
that were used to determine clinical success or
failure. Moreover, many investigators did not
utilize standards similar to those suggested by
the IDSA and SIS [6,23] for evaluating clinical
outcome in trials of antimicrobial therapy for
intra-abdominal infections.
Many different examples of the variable definitions of clinical success or failure were encountered. In a number of studies, clinical failure was defined as the persistence of symptoms
or signs of infection after a limited time period,
whether or not a different antimicrobial treatment regimen was implemented. The SIS and
IDSA guidelines indicate that these patients
should be considered clinical treatment failures
if additional antimicrobial therapy is utilized
or another source control procedure is necessary to treat ongoing infection. As indicated
previously, patients who developed nosocomial infections outside of the abdomen were
also variably described. In some studies, these
patients were considered successfully treated,
in others, they were counted as treatment failures, and in still others, they were excluded
from the final analysis. Also, in a few studies,
patients with adverse events requiring a
change to other antimicrobial agents were reported as treated successfully or were excluded
from the final analysis, although these patients
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should generally be reported as having failed
the initial antimicrobial treatment regimen.
Another problem with the reported success
rates was the lack of uniformity in the timing
of outcome reporting. In general, final outcome
should be determined several weeks after the
end of antimicrobial therapy, and patients for
whom there is incomplete follow-up data
should be considered unevaluable. In a number of publications, however, there was no indication as to when success or failure was determined. Other authors reported success rates
only at the end of therapy, or provided only incomplete follow-up data after the end of therapy. In a few studies, it was apparent that patient outcomes had changed during subsequent
follow-up, and that success rates reported at
the end of therapy had been overstated. Nevertheless, the incomplete follow-up information made it impossible to verify the accuracy
of success rates determined at later time points.
Therefore, success rates reported at the end of
therapy were used as the final measure of outcome in these studies if they were the only ones
available that were based on an assessment of
the entire clinically evaluable population.
Although it might have been desirable to reclassify patient outcomes to bring them more
into line with the SIS and IDSA criteria [6,23],
this would rarely have been possible because
of the limited descriptions of unsuccessful clinical outcomes provided in most publications.
Ultimately, the Committee accepted most of
the investigators’ reported success rates at face
value, and only modified them for a few selected reasons to improve uniformity. If the investigators had not already done so, patients
who were given a final outcome of “improved”
or some similar adjective were included among
the successfully treated patients in recalculating clinical success rates. Patients designated as
“improved” generally required no further antimicrobial therapy, although they might not
have completely resolved all symptoms and
signs of infection. The Committee also recalculated some success rates by excluding patients
with indeterminate outcomes from the denominator, if this had not already been done. In a
few studies, no clinical success or failure rate
was reported, but a description of the adverse
outcomes that occurred in patients enrolled in
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the study was provided. For these studies, the
success rate was calculated as best as possible
using the available information.
Interpretations of outcome were also influenced strongly by the manner in which investigators reported surgical site infections
(“wound infections”). Most studies counted
such patients as therapeutic failures, which is
consistent with the IDSA and SIS criteria [6,23].
In some trials, though, patients with superficial
surgical site infections were considered to be
treated successfully as long as no other complications occurred. Since the development and
identification of superficial surgical site infections in patients with intra-abdominal infections may relate more to surgical decisions regarding wound closure than to the utility of a
specific antimicrobial regimen, it has been recommended that adverse outcomes due only to
superficial surgical site infections be reported
separately from other failures [24].
In some of these studies, in fact, virtually all
the clinical failures were due to “wound infections.” In order to evaluate more serious
failures apart from those due to superficial
surgical site infections, when possible, the
Committee determined the rates of these infections from the information available in the
publications. Further, the Committee calculated additional clinical success rates in which
patients with isolated superficial surgical site
infections were not counted as treatment failures. For these calculations to be valid, however, the numbers of patients who failed therapy exclusively because of superficial surgical
site infections had to be unambiguously
stated. In calculating these additional success
rates, patients with deep surgical site infections, and patients who had reasons aside
from superficial surgical site infections for
failing therapy were still considered as unsuccessfully treated. Although these recalculated success rates are clearly subject to interpretational error, they do provide an
additional measure with which to compare
different trials of antimicrobial therapy for intra-abdominal infections, particularly when
superficial surgical site infections account for
many of the reported adverse outcomes.
By considering the outcome in all patients,
an intention-to-treat (ITT) analysis helps en-
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sure that issues related to patient exclusions
and indeterminate outcomes have not unduly
biased study results. In a few of the trials of
antimicrobials for intra-abdominal infections,
an ITT analysis was provided. In other trials,
a modified ITT analysis was performed. For
these modified ITT analyses, patients might be
excluded because they did not have an intraabdominal infection identified at the time of
surgical intervention, or they did not receive
study medications for some reason. Unfortunately, most publications did not include the
results of either an ITT or a modified ITT
analysis. Many times, only the results obtained
from the clinically evaluable patients were reported.
Other reviewers [24,25] have previously
identified many of the same problems in trial
design, implementation, and interpretation
that were prevalent in the publications reviewed by the Committee. Overall, though, it
appeared that trial quality had improved somewhat over the decade. Several recent large
multi-institutional trials were conducted according to the principles outlined by the IDSA
and SIS. Nevertheless, for the database as a
whole, relatively poor quality data was the rule
rather than the exception. Although potentially
desirable, the Committee did not believe that it
would be possible to rely exclusively on the
larger, higher-quality studies for developing
guidelines without limiting greatly the scope of
the recommendations.
Ultimately, the Committee attempted to integrate the evidence in the database by using
investigators’ reported success rates in clinically evaluable patients as a means of comparing outcome across studies. Where available,
the results of recalculated success rates excluding patients who failed therapy because of
superficial surgical site infections and the results of ITT analyses were also utilized. However, the Committee recognizes that the interpretation of these success rates is problematic
because of the numerous methodological issues described above. Therefore, these reported
clinical success rates can only be used as a
rough guide to the utility of various interventions, particularly when such interventions
have not been compared directly in prospective trials.
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Formulation and approval of the guidelines
Based on this and other evidence, the individual working groups drafted provisional
guidelines in their particular area of investigation, and graded those recommendations. For
grading, the Committee chose the relatively
simple system outlined by the EAST [5], supplemented by descriptions employed by the
American Society for Parenteral and Enteral
Nutrition (Table 4) [21]. Although this grading
system is less complex than others, it still allows a straightforward characterization of the
evidence behind each recommendation. Level
1 guidelines are those having good researchbased evidence to support the recommendation, which usually requires relatively homogeneous Class I evidence. Generally, the
Committee required consistent evidence from
at least two prospective randomized controlled
trials to justify a Level 1 recommendation.
Level 2 guidelines are based on reasonable research-based evidence, which may indicate
some heterogeneity in the results of prospective randomized controlled trials, or the need
to rely primarily on Class II evidence to support the recommendation. Level 3 guidelines are
those based on Class III evidence and expert
opinion. Although Level 1 guidelines can be
considered standards of care, the evidence behind recommendations classified as Level 2 or
Level 3 is insufficient for them to be so considered. Level 3 recommendations, in particular,
identify issues that should be addressed by additional prospective randomized controlled trials or other rigorously-conducted studies.
The entire Committee then refined the recommendations drafted by each working group

TABLE 4.
Level
1

RATING SCALE
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through a process of iterative consensus. A consensus on the grading of each recommendation
was also reached. A preliminary draft of the
guidelines and the evidence behind them was
then submitted to two independent reviewers
from the Society, who were not members of the
Committee. The proposed guidelines were presented at the 21st Annual Meeting of the SIS
(May 3–5, 2001, Snowbird, UT), following
which the two discussants provided their indepth critiques of the recommendations. An
open forum was also held to allow the general
membership of the Society to comment on the
proposed guidelines.
These critiques and discussions were then
used to modify the guidelines into their present form. After final consensus was achieved,
the Committee submitted these guidelines
along with supporting materials to the Council of the SIS. The Council has approved these
guidelines as the official position of the SIS
with respect to antimicrobial therapy for patients with intra-abdominal infections.
PATIENT SELECTION
Most patients undergoing abdominal procedures receive antimicrobials in the perioperative period. Much of this use is intended as prophylaxis, primarily to prevent surgical site
infections. Prophylactic antimicrobials seldom
should be used for longer than 24 h; a single
dose of antibiotic is sufficient for most procedures. The use of prophylactic antimicrobials
is not covered under these guidelines.
The decision to treat a patient with therapeutic (non-prophylactic) antimicrobials re-

FOR

RECOMMENDATIONS

Recommendation
Recommendation based on good research-based evidence. Supported primarily by homogeneous,
prospective, randomized controlled trials, although strong Class II data may be the basis of

the
2
3

recommendation when the issue is not amenable to study with a prospective randomized
controlled trial.
Recommendation based on fair research-based evidence. Supported by limited data from
prospective, randomized controlled trials, or from other prospective or retrospective
analyses with good study design, and strongly supported by expert opinion.
Recommendation based primarily on limited or uncontrolled data and supported by expert
opinion.
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quires that an established intra-abdominal infection be present. Therapeutic antimicrobials
are defined here as those that are given for
greater than 24 h. To fulfill the diagnosis of an
established intra-abdominal infection, not only
must a normally sterile area of the abdominal
cavity be contaminated with infectious material, but also an inflammatory focus must have
become established because of that microbial
inoculum. From the perspective of the surgeon,
this corresponds to an infected site that cannot
be eradicated completely with the primary
source control procedure.
The presence of infectious material, which is
a prerequisite for the development of an intraabdominal infection, is usually apparent at the
time of the initial source control procedure. An
obvious bowel perforation or the presence of enteric fluid implies that contamination with infectious material has occurred. Occasionally,
purulent peritoneal fluid without an obvious enteric source is identified, and it may be less clear
that infectious material is actually present. Under these circumstances, Gram stain and culture
of the fluid may be performed to determine if
microorganisms are actually present, although
these tests prove ambiguous on occasion.
Contamination of the abdominal cavity by
microorganisms is not in itself synonymous
with an established intra-abdominal infection.
The duration of the contamination and the intensity of the reaction must be sufficient to allow for the development of an inflammatory
focus. The abdominal cavity probably needs to
be exposed to infectious material for at least
12–24 h to allow an intra-abdominal infection
to become established. The source and quantity of the infectious material contaminating the
abdomen influences greatly the size of the
microbial inoculum, and thereby the rapidity
with which an infection develops. Nonetheless,
there are no absolute criteria for determining if
intra-abdominal contamination has progressed
to an established infection. Ultimately, the clinician must use the clinical history, radiographic
examinations, and direct intra-operative observations to make this judgment.
The issue as to whether or not an established
intra-abdominal infection is present generates
much of the controversy regarding the selection of patients for therapeutic antimicrobial
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therapy. There are clearly patients who fall into
the gray area between contamination and established infection. Such patients include those
who sustained heavy intra-abdominal contamination before or during an operative procedure, and those who have an infected focus
within the abdominal cavity confined to a specific organ that can be eradicated by an operative procedure. The need for therapeutic antimicrobials in such patients should be based, in
as much as possible, on the results of prospective studies of antimicrobial therapy carried out
in similar patients.
Summary of findings
By far the best evidence concerning which
patients need therapeutic antimicrobials comes
from studies of patients with traumatic bowel
perforations. Based on studies available at the
time, Bohnen et al. [1] recommended that patients with traumatic bowel perforations operated on within 12 h receive 24 h or less of antimicrobial therapy. Three large prospective
randomized controlled trials published in the
past decade have provided additional evidence
to support that recommendation. These studies compared the use of short-term versus
longer-term antimicrobial therapy in patients
with penetrating abdominal trauma [26–28].
Two of these studies [26,28] were restricted to
patients with hollow viscus injuries as a result
of penetrating trauma. Nearly half of the patients in the third study also had such injuries
[27]. In the three studies combined, 852 patients
were evaluated who had been randomized to
receive 24 h versus 5 days of perioperative antibiotics. There were no significant differences
between the two study groups in any of the trials with respect to the numbers of patients developing intra-abdominal infections, which averaged 6–10% in both groups (Table 5). The
total numbers of infections, including those
outside the abdomen, also did not appear to be
influenced by the duration of antimicrobial
treatment. Thus, in patients with penetrating
abdominal trauma and hollow viscus injury,
there does not seem to be any benefit to the use
of prolonged antimicrobial therapy, and prophylactic antibiotics administered for 24 h or
less are appropriate for these patients.
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of sSSI were determined only in patients who had their wounds closed.
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4 Ampicillin/sulbactam dosages were modified according to renal function.
5 The numbers of excluded patients were not reported.
6 Only an ITT analysis was reported.
7 The success rate was 91% if a patient with an isolated sSSI was not considered a treatment failure.
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It is important to note that all patients in
these trials underwent surgical therapy fairly
soon after the injury was sustained. Patients
who were not operated on early or had missed
injuries were excluded from these studies. The
guidelines of Bohnen et al. [1] recommended
short-term antimicrobial therapy only for those
patients whose perforations had been treated
surgically within 12 h. Although this time point
was not directly ascertained on the basis of
prospective data, it still represents a reasonable
estimate of the time required for major contamination to evolve into an established infection.
Although these trials enrolled only patients
with penetrating abdominal trauma, it seems
reasonable to apply the results to other patient
groups. Examples of such patients include
those who have sustained hollow viscus injuries as a result of blunt trauma and those who
have received an iatrogenic bowel injury, such
as a colonoscopic perforation of the colon.
Again, this consideration would apply only if
the operative procedure was performed expeditiously. These results should also apply to patients who have inadvertent enteric contamination during elective abdominal procedures,
since the short duration of contamination
should not result in an established infection. In
these additional patient groups it seems unlikely that prolonged exposure to antimicrobials would produce a clinical benefit that was
not evident in patients who had sustained penetrating hollow viscus injury.
Because of the low numbers of bacteria normally found in the stomach and duodenum,
perforations of the gastrointestinal tract above
the ligament of Treitz generally result in much
less intra-abdominal contamination than perforations of the distal small bowel or colon.
Bohnen et al. [1] indicated that patients with
gastroduodenal perforations less than 24 h old
did not need to be treated with therapeutic antimicrobials. Although a definitive study of this
has not been performed, very limited data and
expert opinions indicate that gastroduodenal
perforations repaired early require less than
24 h of antimicrobial therapy [29–31].
Patients who had an infected focus that could
be eradicated fully at the time of surgical intervention also do not require therapeutic an-
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timicrobials, according to the previous guidelines [1]. Examples of these patients include
those with non-perforated appendicitis, acute
or gangrenous cholecystitis, or bowel necrosis
without perforation. Treatment of such patients
with prophylactic antimicrobial therapy was
examined in two series of patients. Andåker et
al. [29] described 147 patients with acute or
gangrenous appendicitis, 18 patients with
cholecystitis, and 52 patients with small bowel
or colonic obstructions who were treated with
antimicrobials for 24 h or less. Clinical success
rates in these three groups of patients were 98%,
100%, and 90%, respectively (Table 6). Schein et
al. [30] described a series of 92 patients, among
whom were 55 with acute or gangrenous appendicitis, 21 with acute or gangrenous cholecystitis, and four with small bowel necrosis
without perforation. These patients were treated
according to a protocol specifying a maximum
of 24 h of perioperative antibiotics. There were
no major intra-abdominal infectious complications in these patients, and only 4% of the patients developed superficial surgical site infections (Table 6). Overall, infection rates in both
of these series were comparable to those found
in contemporary literature. Thus, there is reasonable evidence that antimicrobial therapy
can be limited to 24 h or less in patients with
acute or gangrenous appendicitis, acute or gangrenous cholecystitis, and those with bowel obstruction or bowel necrosis due to a vascular
accident or strangulation, in whom there is no
evidence of perforation (Table 7). However,
these recommendations do not apply to patients whose infection has extended beyond the
initial anatomic focus and who have purulent,
infected, peritoneal fluid. Since these patients
have established intra-abdominal infections,
therapeutic antimicrobial therapy is warranted.
The guidelines regarding patient selection for
use of therapeutic antimicrobials are summarized in Table 8.

DURATION OF
ANTIMICROBIAL THERAPY
Although patients who do not have established intra-abdominal infections can be
treated with antimicrobials for 24 h or less, the
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SIS AND INTRA-ABDOMINAL INFECTIONS: EVIDENCE
TABLE 7. CONDITIONS FOR WHICH THERAPEUTIC
ANTIMICROBIALS (.24 H ) ARE N OT RECOMMENDED
Traumatic and iatrogenic enteric perforations operated
on within 12 h.
Gastroduodenal perforations operated on within 24 h.
Acute or gangrenous appendicitis without perforation.
Acute or gangrenous cholecystitis without perforation.
Transmural bowel necrosis from embolic, thrombotic, or
obstructive vascular occlusion without perforation or
established peritonitis or abscess.

optimal duration of antimicrobial therapy for
patients with established intra-abdominal infections remains controversial. There is very little Class I evidence that can be used to evaluate this topic, and expert opinions vary widely.
In many prospective trials, duration of therapy
has been left to the discretion of the investigator. Thus, antimicrobial therapy has been permitted for 3–14 days or more, and few criteria
have been specified for eventual discontinuation of antimicrobials.
There is little agreement even with regard to
the clinical determinants that should be used
in establishing optimal duration of treatment.
Some recommend that a fixed duration of antimicrobial therapy be designated at the time
of the initial surgical intervention, based on the
specific pathological findings. Others advocate
continuation of antimicrobial therapy until the
patient’s symptoms and signs of infection have
resolved. Still others promote a combined approach.
One difficulty in determining the optimal
duration of therapy is that a remarkably diverse number of conditions are described as
intra-abdominal infections. These vary from
relatively minor infections, such as a peri-appendiceal abscess, to severe infections, such as
a massive retroperitoneal infection associated
with extensive peri-pancreatic necrosis. Patients with the former conditions might be
treated adequately with very short courses of
antimicrobials, whereas patients with the latter conditions might need more prolonged
therapy. In fact, it may be impossible to
achieve adequate source control in patients
with these latter conditions, and antimicrobial
therapy may ultimately be unsuccessful, regardless of its duration.
One potential approach to the diversity of
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conditions described as intra-abdominal infections would be to utilize systems that stratify
patients according to the type and source of infection, such as that outlined by Meakins et al.
[32]. Such systems could define cohorts of patients for investigations of optimal duration of
antimicrobial therapy. Unfortunately, such
stratification schemes have not been used
widely in clinical trials up to now.
Thus, there has not yet been a sufficiently
powered, prospective randomized controlled
clinical trial performed that has evaluated adequately the duration of antimicrobial therapy
for patients with intra-abdominal infections.
This lack of data may be explained by the logistical difficulties of studying this complex
population of patients, as well as the lack of a
commercial incentive to carry out such trials,
whose results might lead to decreased use of
antimicrobials. The evidence that can be used
to formulate recommendations on this topic,
therefore, is limited to that obtained from small
prospective studies, retrospective studies, and
expert opinions.
Summary of findings
There is a growing consensus that prolonged
courses of antimicrobial agents are not necessary
for many patients with intra-abdominal infections. In the previous guidelines, Bohnen et al.
[1] recommended 5–7 days of antimicrobial ther-

TABLE 8.

GUIDELINES FOR SELECTION OF PATIENTS
R EQUIRE THERAPEUTIC (.24 H ) VERSUS
PROPHYLACTIC ANTIMICROBIALS (,24 H )

WHO

1. Patients with peritoneal contamination due to
traumatic or iatrogenic bowel injuries repaired
within 12 h (Level 1), and those having
gastroduodenal perforations less than 24 h old
(Level 3) are not considered to have established
intra-abdominal infections, and should be treated
with prophylactic antimicrobials for 24 h or less.
2. Patients with a fully removable focus of
inflammation, such as those with acute or
gangrenous, but non-perforated appendicitis or
cholecystitis, and those with bowel necrosis or
obstruction without perforation or peritonitis, should
be treated with prophylactic antimicrobials for 24 h
or less (Level 2).
3. Patients with more extensive conditions than those
noted above should be treated as having established
infections, and given therapeutic antimicrobials for
greater than 24 h (Level 3).
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apy for most patients. More recently, Wittmann
and Schein [31] proposed even shorter durations
of therapy. Although there are no Class I studies addressing this issue specifically, some evidence supporting shorter duration of antimicrobial use can be gleaned from reports of
protocols that limited the duration of therapy
based on the initial operative findings. In the
study described previously by Andåker et al.
[27], antimicrobials were limited to 5 days in a
cohort of 84 patients with intra-abdominal infections. Similarly, in the study by Schein et al.
[28] antimicrobials were limited to 48 h in 48 patients with localized peritonitis, and to three to
five days in 23 patients with diffuse peritonitis.
In both studies, the reported success rates for
these patients ranged from 83%–100% (Table 6).
These success rates are comparable to those reported in contemporary literature for patients
with similar disease processes, who generally received longer courses of antimicrobials.
As an alternative to a fixed duration of therapy, antimicrobials could be discontinued when
the patient’s symptoms and signs of infection
resolve. The risk of treatment failure appears to
be quite low in patients who have no clinical
evidence of infection at the time of cessation of
antimicrobial therapy [33,34]. This usually implies that the patient’s temperature and white
blood cell count has normalized, and bowel
function has returned. In a Class II study by
Smith et al. [35], patients with peritonitis from
appendiceal and non-appendiceal sources had
antimicrobials discontinued after four days of
therapy if clinical evidence of infection had
abated. Compared to historical controls, these
patients received fewer doses of antibiotics and
had no increase in infectious complications
(Table 9). In a prospective randomized controlled trial, Taylor et al. [36] evaluated the need
for prolonged antimicrobial therapy in two
groups of patients with complicated appendicitis. In one group, all patients received a minimum of 5 days of intravenous antibiotics, but
in the second group, no minimum duration of
antibiotic therapy was specified. Eventual discontinuation of antibiotics in both groups was
based on clinical criteria. The duration of antibiotic use was significantly longer in the group
assigned to a minimum of 5 days of antimicrobial therapy, but there was no difference be-

MAZUSKI ET AL.

tween the two groups in the numbers of infectious complications. Thus, limiting the duration
of antimicrobial therapy on the basis of clinical
signs and symptoms seems reasonable according to the evidence provided by these studies.
Unfortunately, this conclusion is clouded somewhat because many of the patients in these
studies did not need prolonged antimicrobial
therapy, as they had gangrenous appendicitis
or intra-abdominal contamination only.
Although these data suggest that antimicrobial therapy can be limited in patients with intra-abdominal infections who show improvements in their clinical signs and symptoms, they
do not address the problematic patient who
does not show similar improvements after a
prescribed course of antimicrobials. Several investigators have determined that patients with
persistent clinical evidence of infection at the
time of discontinuation of antimicrobials are
likely to develop subsequent infectious complications. Studies by Lennard et al. [33,34], among
others, identified persistent fever and leukocytosis as predictors of clinical failure.
When patients have persistent clinical signs
of infection, the tendency of many clinicians is
to prolong the course of antimicrobial therapy,
using the same or different agents. However,
there are few, if any data demonstrating that
this approach improves patient outcome. In
fact, Lennard et al. [33,34] did not advocate
such an approach. In their studies, most of the
patients with persistent clinical signs of infection were eventually found to have a new or
recurrent intra-abdominal infection. Thus, they
felt that a search for the source of the persistent clinical signs, along with an appropriate
procedure to adequately control that source,
would have ultimately been much more beneficial than either prolongation of the same antimicrobial therapy or a change to other agents.
However, there is some evidence that a more
prolonged course of antimicrobials is warranted in certain highly selected patients.
Visser et al. [37] analyzed retrospectively a series of patients managed using an open abdominal technique because of refractory peritonitis. Decreased duration of antimicrobial
treatment was identified as a risk factor for
failure in these patients. The authors recommended that antimicrobials not be discontin-
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protocol criteria for discontinuation of antibiotics included a temperature of less than 38°C orally or 38.5°C rectally during the preceding 24 h, a reduction
of the white blood cell count by 10% or more, the passage of flatus, and two of four minor criteria (absence of rebound tenderness, absence of wound infection,
negative blood culture, and absence of clinical or radiological evidence of an abscess).
2 The only complications reported were sSSI. It is uncertain if other therapeutic failures occurred.
3 In patients with non-appendiceal disease, the duration of antimicrobial therapy was significantly shorter (p , 0.001) in the group treated according to the
protocol.
4 The antimicrobial regimen in most patients was ampicillin/sulbactam preoperatively and postoperatively followed by oral cephalexin after cessation of intravenous therapy. Dosages were not reported.
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ued in such patients if there was ongoing clinical evidence of infection. It seems reasonable
to utilize a longer course of antimicrobial therapy in similar patients in whom it is difficult
or impossible to achieve primary source control. However, such considerations apply to
only a small number of patients, such as those
with infected peri-pancreatic necrosis, in whom
an adequate primary source control procedure
may not be feasible, or those with tertiary peritonitis, who have repeatedly failed previous
therapeutic efforts.
Based on the limited data and the opinions
of members of the SIS, therefore, the Committee recommends that antimicrobial therapy be
limited to no more than five to seven days for
most patients with complicated intra-abdominal infections (Table 10). It seems reasonable to
base the maximum duration of antimicrobial
therapy on the extent of the infection identified
at the time of the initial source control procedure, and to discontinue therapy when clinical
symptoms and signs of infection abate. In patients with persistent clinical evidence of infection after the completion of a predetermined
course of antimicrobial therapy, an attempt
should be made to determine the source of that
problem. Patients with persistent or recurrent
intra-abdominal infections are unlikely to respond just to prolongation of antibiotic therapy
with the same or a modified regimen, but
rather will likely require additional therapeu-

TABLE 10. GUIDELINES FOR THE DURATION
ANTIMICROBIAL THERAPY FOR ESTABLISHED
INTRA -ABDOMINAL INFECTIONS

OF

1. Antimicrobial therapy of most established intraabdominal infections should be limited to no more
than 5 (Level 2) to 7 days (Level 3). The duration of
antimicrobial therapy for intra-abdominal infections
can be based on the intra-operative findings at the
time of initial intervention (Level 3). Antimicrobial
therapy can be discontinued in patients when they
have no clinical evidence of infection such as fever
or leukocytosis (Level 2).
2. Continued clinical evidence of infection at the end
of the time period designated for antimicrobial
therapy should prompt appropriate diagnostic
investigations rather than prolongation of
antimicrobial treatment (Level 3).
3. If adequate source control cannot be achieved, a
longer duration of antimicrobial therapy may be
warranted (Level 3).

tic efforts to achieve definitive source control.
Patients with nosocomial infections at extra-abdominal sites will need appropriate antimicrobial therapy directed at those problems. If a patient has persistent clinical symptoms and signs,
but no evidence of a new or persistent infection
is uncovered after a careful investigation, a trial
observation off all antimicrobial therapy is warranted, since the persistent clinical symptoms
and signs may be the result of ongoing sterile
tissue inflammation or drug-induced hyperthermia, and not due to infection [31]. However,
it is prudent to monitor carefully such patients
for recurrent intra-abdominal infection, which
could still develop.

ANTIMICROBIAL REGIMENS FOR
INTRA-ABDOMINAL INFECTIONS
The fundamental principles of antimicrobial
therapy for intra-abdominal infections were
outlined over 25 years ago, and have not
changed substantially in the interim. These
principles were based on experimental models
of intra-abdominal infections and subsequent
clinical studies, which demonstrated that antimicrobial regimens should cover common
aerobic/facultatively anaerobic Enterobacteriaceae such as Escherichia coli, and anaerobic organisms, particularly Bacteroides fragilis [38,39].
Although the initial regimens shown to be efficacious included an aminoglycoside, such as
gentamicin, combined with an antianaerobic
agent, such as clindamycin, the repertoire of
antimicrobial agents has expanded greatly over
the past two decades, and many single agents
or combination regimens are now available for
the treatment of patients with intra-abdominal
infections.
In the previous guidelines, Bohnen et al. [1]
identified second-generation cephalosporins
with anaerobic coverage (cefoxitin, cefotetan,
cefmetazole), ticarcillin/clavulanic acid, and
imipenem/cilastatin as acceptable single-agent
therapy. Appropriate combination regimens
included an aminoglycoside (gentamicin, tobramycin, netilmicin, or amikacin) plus an
antianaerobic agent (clindamycin or metronidazole), a third-generation cephalosporin (cefotaxime, ceftizoxime, ceftazidime, or ceftriax-
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one) plus an antianaerobic agent, and aztreonam plus clindamycin for the treatment of
patients with intra-abdominal infections.
Over the past decade, a number of prospective randomized controlled trials have evaluated further these agents, as well as others
such as ampicillin/sulbactam, piperacillin/
tazobactam, meropenem, ertapenem, and cefuroxime, cefepime, ciprofloxacin combined
with metronidazole, for which little definitive
information was available prior to 1990. The results of these and selected earlier trials are summarized individually in Table 11, to which the
reader is referred during the subsequent discussions of specific antimicrobial regimens.
The Committee used this body of Class I data,
supplemented by limited amounts of Class II
and Class III data, to expand the list of acceptable antimicrobial regimens for the treatment
of patients with complicated intra-abdominal
infections.
Ideally, these data would identify those antimicrobial agents most effective for treating intra-abdominal infections. The Committee could
then designate those agents as preferred or
first-line therapy for this indication. However,
the Committee found it impossible to make
such determinations on the basis of therapeutic superiority. Few trials reported a statistically significant difference in outcome between
treatment arms, and those that did so tended
to be smaller, lower-quality studies. Moreover,
in several studies, the observed differences in
outcome were related primarily to rates of superficial surgical site infections, and not to
more serious infectious complications. In general, the larger, higher-quality studies demonstrated few statistically significant differences
in outcome between different regimens.
A further problem with designating preferred antimicrobial regimens was that very
few of the trials were actually designed to detect therapeutic superiority. Many investigators did not include a power analysis in their
descriptions of trial design, that is, there was
no estimate of the number of patients that
would be needed to detect a specific difference
between the treatment groups. Among those
that did provide this information, the trials
were usually powered only to detect therapeutic equivalence, or more correctly, non-in-
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feriority, and not therapeutic superiority. Thus,
many of these trials were only designed to detect a true difference of greater than 10–15% between treatment arms.
The technique of meta-analysis can be used
to combine the results of studies that individually are powered insufficiently to detect measurable differences in outcome. In actuality,
however, the Committee found that very few
meta-analyses related to antimicrobial therapy
for patients with intra-abdominal infections.
Although the Committee did utilize the reported and calculated clinical success rates as
a rough guide to compare the results of different therapeutic regimens, this was done without undertaking a formal meta-analytic review.
In any case, the results of such meta-analyses
would have to have been interpreted with extreme caution, since the component trials had
such widely varying design and quality.
In the end, the Committee concluded that the
information from the database could be used
to identify effective antimicrobial regimens for
the treatment of patients with intra-abdominal
infections, but not to specify therapeutically superior regimens. Preference for one regimen
over another would need to be based on criteria other than the therapeutic efficacies reported in the published literature.
Another issue that proved problematic for
the Committee was the applicability of these
antimicrobial recommendations to different
groups of patients with intra-abdominal infections. To evaluate this, the Committee reviewed the diagnoses of the clinically evaluable patients enrolled in the various trials.
Overall, it appeared that most of the patients
had relatively easy-to-treat community-acquired infections, such as complicated appendicitis. In fact, in ten trials, enrollment
was limited to such patients, and in many
others, the majority of the evaluable patients
had an appendiceal source of infection. The
conclusion that most patients enrolled in
these studies were less severely ill was confirmed by the relatively low mortality rates
found in most trials, as will be discussed subsequently. Therefore, the recommendations
outlined in this section pertain primarily to
the treatment of lower-risk patients with
community-acquired intra-abdominal infec-

[43]
Kooi, 1990

[42]
Study Group,
1986

[41]
Yellin, 1985

[40]
Malangoni,
1985

Reference

Netilmicin
2 mg/kg tid
1
Metronidazole
7.5 mg/kg tid

Ceftazidime
20 mg/kg tid
1
Metronidazole
7.5 mg/kg tid

Gentamicin
1.5 mg/kg q8h1
1
Clindamycin
600 mg q6h

NR6

61

503

503

374

464

62

Ampicillin/
sulbactam
3 g q6h

3

673

533

59

38

197

88

82

Gentamicin
1.5 mg/kg q8h1
1
Clindamycin
600 mg q6h

Ampicillin/
sulbactam
3 g q6h

Tobramycin
1.5 mg/kg q8h1
1
Clindamycin
600 mg q6h

Cefoxitin
3 g q6h

Antimicrobial
agents

OF

ANTIMICROBIAL REGIMENS
FOR

PATIENTS
WITH

INTRA -ABDOMINAL INFECTIONS

82%7

98%7

97%5

87%5

100%

3

88%3

79%3

83%

18%8

0%3

NR

0%

3

6%3

4%3

3%

98%

98%

N/A

100%

94%

83%

86%

NR

NR

NR

NR

0%

0%

NR

0%

0%

6%

8%

100%

100%

NR

100%

100%

17%

22%

1

4

4

5

No

No

No

Yes2

No

No

No

Probably
not

Success
Complicated
Number Number
rate
Percentage
infections
of
of
Reported Percentage excluding
of patients
APACHE
per
patients evaluable success of patients isolated
ITT
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Quality
II
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enrolled patients
rate
with sSSI
sSSI
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score
scoring?
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[47]
Poenaru,
1990

[46]
Bubrick,
1990

[45]
Swedish
Study
Group,
1990

[44]
Jauregui,
1990

47

52

52

Imipenem/cilastatin
500 mg q6h

Tobramycin
1.5–2 mg/kg q8h1
1
Clindamycin
600 mg q6h
or
Metronidazole
500 mg q6h

47

Ceftazidime
2 g q8h
1
Clindamycin
900 mg q8h

Tobramycin
1.5–2 mg/kg12
1
Clindamycin
900 mg q8h

135

136

52

100

Gentamicin
1.5 mg/kg q8h1
1
Metronidazole
500 mg q8h

Pefloxacin
800 mg, then
400 mg q12h
1
Metronidazole
500 mg q8h

Gentamicin
1.5–2 mg/kg q8h1
1
Clindamycin
600–800 mg q6–8h

Cefoperazone/
sulbactam
3 g q12h

4613

4813

34

34

7811

10411

349

769

76%13

85%13

91%5

91%5

82%5

90%5

74%5,10

93%5,10

NR

9%

6%

NR

NR

N/A

100%

97%

N/A

N/A

NR

NR

NR

NR

1714

8%14

NR

3%

0%

NR

NR

NR

65%

61%

NR

1

1

1

3

12.1

11.2

No

No

No

Yes

No

No

No
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[50]
Schropp,
1991

[49]
Sirinek,
1991

[48]
Solomkin,
1990

Reference

TABLE 11.

Gentamicin
2–2.5 mg/kg q8h20
1
Clindamycin
10 mg/kg q8h
1
Ampicillin
50 mg/kg q6h
15421
47

50

Cefotaxime
25 mg/kg q6h
1
Clindamycin
10 mg/kg q8h

56

81

819

43

NR19

142

148

Gentamicin
1.5 mg/kg q8h
(2 mg/kg q8h)1,18
1
Clindamycin
600 mg q6h
(10 mg/kg q6h)18

Ticarcillin/
clavulanic acid
3.1 g q6h
(75 mg/kg q6h)18

Tobramycin
1.5 mg/kg q8h1
1
Clindamycin
600 mg q6h15

Imipenem/
cilastatin
500 mg q6h15

Antimicrobial
agents

OF

ANTIMICROBIAL REGIMENS
FOR

PATIENTS
WITH

INTRA -ABDOMINAL INFECTIONS (CONT’D )

89%

96%

84%

86%

70%16

83%16

2%

0%

14%

5%

2%

4%

91%

96%

98%

91%

73%

86%

NR

NR

NR

NR

0%

0%

17%

14%

100%

100%

100%

100%

20%

28%

5

1

2

No

No

Yes17

No

No

Yes

Success
Complicated
Number Number
rate
Percentage
infections
of
of
Reported Percentage excluding
of patients
APACHE
per
patients evaluable success of patients isolated
ITT
with
Quality
II
IDSA
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rate
with sSSI
sSSI
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scoring?
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[54]
Eckhauser,
1992

[53]
Meller, 1991

[52]
Luke,
1991

[51]
Williams,
1991

79

66

Imipenem/cilastatin
500 mg q6–8h22,29

Gentamicin or
Tobramycin
1 mg/kg q8h1
1
Clindamycin
600 mg q6h

5928

Gentamicin,1,27
1
Clindamycin27

Cefoxitin27

10225

9925

Ceftriaxone
1 g qd24
1
Metronidazole
1.5 g qd24

Netilmicin
150 mg bid24
1
Metronidazole
1.5 g qd24
1
Ampicillin
2 g bid24

161

155

Tobramycin
3–5 mg/kg/day1,22
1
Clindamycin
1.8–4.8 g/day22,23

Aztreonam
3–8 g/day22
1
Clindamycin
1.8–4.8 g/day22,23

64

53

27

29

96

94

105

104

92%5

96%5

78%

93%

81%26

94%26

85%

85%

NR

7%

3%

9%

1%

NR

N/A

85%

97%

91%

95%

N/A

NR

NR

NR

NR

5%14

3%14

NR

5%

4%

2%

4%

25%

11%

100%

100%

33%

47%

42%

50%

1

1

2

2

No

No

No

No

Probably
not

No

No

Probably
not
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[57]
Barboza,
1994

[56]
Polk, 1993

[55]
Berne, 1993

Reference

TABLE 11.

Amikacin
5 mg/kg q8h
1
Clindamycin
900 mg q8h

Aztreonam
2 g q8h
1
Clindamycin
900 mg q8h

Gentamicin
2.5–5 mg/kg/day
divided q8–12h1
1
Clindamycin
600 mg q6h

34

33

114

31

31

43

104

Piperacillin/
Tazobactam
3.375 g q6h
217

46

156

50

Gentamicin
1.5 mg/kg q8h1
1
Clindamycin
900 mg q8h

Cefepime
2 g q12h
1
Metronidazole
500 mg q8h

Antimicrobial
agents

OF

ANTIMICROBIAL REGIMENS
FOR

PATIENTS
WITH

INTRA -ABDOMINAL INFECTIONS (CONT’D )

94%5

100%5

77%5

88%5

83%

94%

6%

13%

NR

4%

0%

94%30

100%30

N/A30

87%

94%

NR

81%

88%

NR

3%

3%

4%14

3%5

0%

0%

58%

58%

49%

56%

100%

100%

2

1

2

No

No

No

Probably
not

Probably
not

No

Success
Complicated
Number Number
rate
Percentage
infections
of
of
Reported Percentage excluding
of patients
APACHE
per
patients evaluable success of patients isolated
ITT
with
Quality
II
IDSA
enrolled patients
rate
with sSSI
sSSI
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score
scoring?
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[61]
Shyr
1995

[60]
Dougherty,
1995

[59]
Hopkins,
1994

[58]
Greenberg,
1994

Gentamicin
2.5–5 mg/kg/day
divided q8–12h1
1
Clindamycin
600 mg q6h

Piperacillin/
tazobactam
4.5 g q8h

Gentamicin
(2–2.5 mg/kg
q8h)1,18
1
Clindamycin
1200–2700 mg/day
(25–40 mg/kg/day)
1
Ampicillin
(12.5 mg/kg q6h)18

Ticarcillin/
clavulanic acid
3.1 g q4–6h
(200–300 mg/kg/
day)18,22

Amikacin
500 mg, then
7.5 mg/kg q12h
1
Clindamycin
600 mg q6h

30

47

34619

64019

55

30

46

137

204

3613

4013

Cefotetan
2 g q12h
58

29

87

47

Gentamicin1
1
Clindamycin
900 mg q8h

Cefoperazone/
sulbactam
3 g q12h22

97%

98%

84%5

86%5

86%13

90%13

NR31

NR

5%

3%

0%

8%

NR

N/A

89%

89%

86%

98%

N/A30

NR

77%

83%

NR

52%32

70%32

0%

0%

2%

2%

NR

10%

13%33

23%34

30%34

NR

100%

100%

28%

34%

3

1

4

3

No

No

No

No

No

Probably
not

No

No
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[65]
Ciftci,
1997

[64]
Wilson,
1997

[63]
Berne,
1996

[62]
Condon,
1995

Reference

TABLE 11.

Tobramycin
1.33 mg/kg tid
1

Tobramycin
1.33 mg/kg tid
1
Clindamycin
10 mg/kg qid
1
Penicillin
25,000 units/kg q3h
NR35

212

215

Meropenem
1 g q8h

Tobramycin
1.67 mg/kg q8h1
1
Clindamycin
900 mg q8h

110

118

89

88

Tobramycin
1.67 mg/kg q8h1
1
Clindamycin
900 mg q8h

Meropenem
1 g q8h

Tobramycin
1.67 mg/kg q8h1
1
Clindamycin
900 mg q8h

Meropenem
1 g q8h

Antimicrobial
agents

OF

ANTIMICROBIAL REGIMENS
FOR

PATIENTS
WITH

INTRA -ABDOMINAL INFECTIONS (CONT’D )

50

94

97

66

63

63

64

92%11

93%5

96%5

91%

92%

89%

92%

4%

NR

0%

0%

2%

0%

96%

N/A

91%

92%

90%

92%

NR

94%

96%

NR

65%

70%

0%

1%

1%

0%

0%

2%

2%

100%

72%

73%

100%

100%

38%

34%

2

5

4

4

No

Yes2

No

Yes2

No

Probably
not

No

No

Success
Complicated
Number Number
rate
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per
patients evaluable success of patients isolated
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Quality
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rate
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[68]
Cometta,
1994

[67]
Leal del
Rosal,
1995

[66]
Torres,
2000

Imipenem/
cilastatin
500 mg qid
1
Netilmicin
150 mg bid

Imipenem/
cilastatin
500 mg qid
31336

89

178

Isepamicin
15 mg/kg qd
1
Metronidazole27

Amikacin
7.5 mg/kg bid
1
Metronidazole27

80

Gentamicin
80 mg q8h
1
Metronidazole
500 mg q8h

39

39

70

135

731

76

80

Cefminox
2 g q12h

92%37

79%37

94%5

96%5

96%13

99%13

96%

92%

50

50

92%

50

Ceftriaxone
25 mg/kg bid
1
Ornidazole
10 mg/kg bid

Ornidazole
10 mg/kg bid
1
Penicillin
25,000 units/kg q3h
Piperacillin
67 mg/kg tid

NR

NR

18%

11%

4%

8%

4%

N/A

N/A

96%30

99%30

100%

100%

96%

NR

94%

95%

88%

94%

NR38

0%

1%

1%

0%

0%

0%

0%

0%

0%

NR

66%

53%

100%

100%

100%

3

1

2

Yes39,40

No

3.2

3.7

Probably
not

Probably
not

No
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[72]
Hollender,
1989

[70]
Dupont,
2000

[69]
HoogkampKorstanje,
1995

Reference

TABLE 11.

81

Piperacillin/
tazobactam
4 g qid

Netilmicin
1.5 mg/kg tid1,44
1
Metronidazole
500 mg tid45,46
56

5547

57

Netilmicin
4.5 mg/kg qd1,44
1
Metronidazole
500 mg tid45,46
58

78

Piperacillin/
tazobactam
4 g qid
1
Amikacin
7.5 mg/kg bid1
241

39

NR

40

Cefotaxime
1 g qid
1
Gentamicin
120 mg bid42
1
Metronidazole
500 mg tid

Ciprofloxacin
300 mg bid41
1
Metronidazole
500 mg tid

Antimicrobial
agents

OF

ANTIMICROBIAL REGIMENS
FOR

PATIENTS
WITH

INTRA -ABDOMINAL INFECTIONS (CONT’D )

98%5

100%5

51%

51%

56%5,43

78%5,43

4%

2%

NR

NR

98%30

100%30

N/A

N/A

NR

48%

44%

NR

2%

0%

21%14

19%14

13%

20%

80%

75%

9%34

9%34

4%

3

3

0

No

No

No

No

Yes

Probably
not

Success
Complicated
Number Number
rate
Percentage
infections
of
of
Reported Percentage excluding
of patients
APACHE
per
patients evaluable success of patients isolated
ITT
with
Quality
II
IDSA
enrolled patients
rate
with sSSI
sSSI
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score
scoring?
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[78]
Jaccard,
1998

[77]
Niinikoski,
1993

[76]
Brismar,
1992

[75]
Allo,
1999

[74]
Walker,
1993

[73]
de Vries,
1990

47

Piperacillin/
tazobactam
4.5 g q8h

Piperacillin/
tazobactam
4.5 g tid29

37152

39

Imipenem/
cilastatin
1 g q8h

Imipenem/
cilastatin
500 mg qid29

69

12249

Ticarcillin/
clavulanic acid
3.1 g q6h29

Piperacillin/
tazobactam
4.5 g q8h

12849

Imipenem/cilastatin
1 g q6h

65

194

Ampicillin/
sulbactam
3 g q6h29

Imipenem/cilastatin
1 g q8h

191

211

Cefoxitin
2 g q6h29

Netilmicin
2 mg/kg tid1
1
Tinidazole
800 mg qd48

Netilmicin
6 mg/kg qd1
1
Tinidazole
800 mg qd48

7653

8353

30

26

55

58

64

73

96

101

76

80

95%37

93%37

87%5

77%5

93%50

69%5,50

97%5

96%5

86%

78%

96%5

93%5

NR

NR

0%

2%

NR

1%

0%

9%

15%

N/A

N/A

93%

71%

N/A

87%

78%

96%30

93%30

NR

NR

84%51

68%51

96%

95%

NR

NR

1%54

2%54

4%14

3%14

0%14

6%14

NR

NR

NR

12%

17%

30%34

15%34

52%34

57%34

100%

100%

33%

35%

31%

41%

2

1

2

2

4

3

8.3

7.3

No

No

No

No

7.9

7.5

No

No

No

Probably
not

Probably
not

No
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[81]
Röhrborn,
2000

[80]
Cohn,
2000

[79]
Ohlin
1999 ,

Reference

TABLE 11.

60

62

Cefotaxime27,58
or
Ceftriaxone27,58
1
Metronidazole27

Piperacillin/
tazobactam27,58
or
Mezlocillin27,58
1
Metronidazole27

224

235

Ciprofloxacin
400 mg q12h
1
Metronidazole
500 mg q6h56

Piperacillin/
tazobactam
3.375 g q6h

140

129

Piperacillin/
tazobactam
4.5 g q8h

Cefuroxime
1.5 g q8h
1
Metronidazole
1.5 g q24h

Antimicrobial
agents

OF

ANTIMICROBIAL REGIMENS
FOR

PATIENTS
WITH

INTRA -ABDOMINAL INFECTIONS (CONT’D )

55

55

116

134

102

91

64%

80%

63%57

74%57

90%55

91%55

13%

11%

19%

11%

2%

1%

N/A

67%57

77%57

92%

92%

NR

69%

75%

74%

70%

7%

9%

4%14

6%14

2%14

3%14

24%

25%

38%

31%

74%

67%

2

3

2

Yes2

9.5

9.6

No

No

No

No

Success
Complicated
Number Number
rate
Percentage
infections
of
of
Reported Percentage excluding
of patients
APACHE
per
patients evaluable success of patients isolated
ITT
with
Quality
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IDSA
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rate
with sSSI
sSSI
analysis Mortality appendicitis
score
scoring?
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[88]
Wilson,
1988

[87]
Lewis,
1988

[86]
Donahue,
1998

[85]
Yoshioka,
1991

[83]
Scheinin,
1994

[82]
Paakkonen,
1991

Cefotetan
2 g q12h

Moxalactam
2 g q8h

Cefoxitin
1–2 g q6h22

271

66

109

56

43

95

122

Cefotetan
1–2 g q12h22

156

40

38

152

414

40

40

53

Imipenem/
cilastatin
1 g q8h64

Alatrofloxacin
300 mg qd63

Amoxacillin/
clavulanic acid
1.2 g q8h61
1
Metronidazole
500 mg q12h62

Ciprofloxacin
200 mg q12h
1
Metronidazole
500 mg q12h60

Piperacillin
4 g qid59

50

Aspoxicillin
4 g qd59
111

38

85

45

Piperacillin
4 g q6h

Cefuroxime
1.5 g q8h
1
Metronidazole
500 mg q8h

94%5

NR

0%

95%5

91%5

0%

1%

1%

NR

8%

4%

11%

9%

98%5

84%5

83%5

90%5

97%5

91%

90%13

71%

64%

N/A

95%

98%

85%

84%

N/A

N/A

N/A

NR

NR

NR

NR

NR

NR

NR

0%14

2%14

5%14

5%14

NR

4%

6%

8%

4%

47%

48%

26–33%66

25–26%66

47%

52%

NR

38%

33%

29%

33%

1

1

3

2

1

1

No

No

7.0

6.4

No

No

No

Probably
not

No

No65

No

No

No
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[93]
Kempf,
1996

[92]
Huzinga,
1995

[91]
Angerås,
1996

[90]
Christou,
1996

[89]
Holloway,
1989

Reference

TABLE 11.

46

48

Meropenem
1.0 g q8h

Cefotaxime
1 g q8h
1
Metronidazole
500 mg q8h

83

77

Meropenem
2 g q8h29

Cefotaxime
2 g q8h29
1
Metronidazole
500 mg q8h

257

258

Imipenem/
cilastatin
1.5–2.0 g/day

Cefuroxime
3.0–4.5 g/day
1
Metronidazole
1.0–1.5 g/day

109

104

27

52

Cefoxitin
2 g q6h

Imipenem/
cilastatin
1 g q6h

Cefoxitin
2 g q6h68

Cefmetazole
2 g q8h67

Antimicrobial
agents

OF

ANTIMICROBIAL REGIMENS
FOR

PATIENTS
WITH

INTRA -ABDOMINAL INFECTIONS (CONT’D )

40

43

78

70

145

161

80

74

7369

75%5,74

95%5,74

100%5,72,73

91%5,72,73

91%5

87%5

84%

88%

92%70,71

0%

0%

NR

NR

0%

0%

NR

75%

95%

N/A

N/A

84%

88%

N/A

NR

NR

86%

83%

82%

83%

NR

4%75

2%75

1%14

3%14

5%14

7%14

3%

3%

3%14

35%

40%

40%

27%

46%

45%

28%34

25%34

48%34

47%34

1

1

2

3

1

Yes2

Yes2

Yes2

7.7

8.9

No

No

No

Probably
not

Yes

No

Success
Complicated
Number Number
rate
Percentage
infections
of
of
Reported Percentage excluding
of patients
APACHE
per
patients evaluable success of patients isolated
ITT
with
Quality
II
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[97]
Solomkin,
1996

[96]
de Groot,
1993

[95]
Barie,
1997

[94]
Mehtar,
1997

219

230

Ciprofloxacin
400 mg q12h86
1
Metronidazole
500 mg q6h85,86

Imipenem/
cilastatin
500 mg q6h85
113

106

111

Ciprofloxacin
400 mg q12h
1
Metronidazole
500 mg q6h85
222

42

104

38

95

122

4677

5177

Aztreonam
1 g q8h29
1
Clindamycin
600 mg q8h

Imipenem/
cilastatin
1 g q6h29

164

159

Imipenem/
cilastatin
500 mg q6h

Cefepime
2 g q12h
1
Metronidazole
500 mg q6h or
7.5 mg/kg q6h

8076

8176

Cefotaxime
1 g tid
1
Metronidazole
500 mg tid

Meropenem
1 g tid29

81%

86%

84%

71%

76%

88%79

76%79

96%78

96%78

1%

2%

3%

17%

16%

0%

2%80

0%

0%

81%

88%

86%

88%

92%

88%

78%

96%

96%

81%

84%

82%

NR

82%

76%

NR

9%

11%

5%

5%

3%

2%

7%

NR

25%

36%

24%

24%83

53%83

33%

33%

NR

4

2

4

2

10.5

9.2

9.2

1184

784

7.882
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Antimicrobial
agents

[103]
Brismar,
1996

[102]
Zanetti,
1999

[101]
Basoli,
1997

[100]
Geroulanos,
1995

[99]
Brismar,
1995

58

Biapenem
500 mg q8h
60

79

82

Meropenem
500 mg q8h29

Imipenem/
cilastatin
500 mg q6h29

139

148

Meropenem
1 g q8h29

Imipenem/
cilastatin
500 mg q8h29

116

116

Meropenem
1 g q8h29

Imipenem/
cilastatin
1 g q8h29

117

Imipenem/
cilastatin
1 g q8h

40

43

6488

7188

101

100

88

82

90

99

31

32

132

28

30

Meropenem
500 mg q8h

Imipenem/
cilastatin
1 g q6h
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68%

65%

94%5

92%5

98%

95%

94%5
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96%

NR

NR

NR

NR

NR

0%

100%5

98%

0%

100%5

N/A

N/A

N/A

N/A

N/A

100%

100%

62%

62%

86%

82%

NR

NR

85%87

94%87

NR

5%14

3%14

6%14

6%14

NR

3%14

5%14
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1%

NR
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39%
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Meropenem
[98]
1 g q8h
Kanellakopoulou,
1993
Imipenem/
cilastatin
1 g q8h

Reference
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Gentamicin
1.5 mg/kg q8h1
1
Clindamycin
600 mg q6h

Gentamicin
1.5 mg/kg q8h1
1
Clindamycin
900 mg q8h
NR

6489

13189

Gentamicin or
Tobramycin
6–7.5 mg/kg/day
1
Ampicillin/
Sulbactam
150–300 mg/kg/day

Gentamicin or
Tobramycin
6–7.5 mg/kg/day
1
Clindamycin
20–40 mg/kg/day
1
Ampicillin
200 mg/kg/day

310

Piperacillin/
tazobactam
3.375 g q6h85

323

46

80

39

75

193

203

91%

93%

97%5

97%5

81%

87%

7%

3%

NR

4%

3%

98%

95%

N/A

85%

90%

NR

NR

76%83

79%83

2 Distributions

dosing was modified according to renal function or serum drug concentrations.
of APACHE II scores were provided.
3 Significantly different (p 5 0.03) in favor of gentamicin plus clindamycin.
4 Four patients in the clinically evaluable population had soft tissue infections.
5 Success rates include patients reported as cured or improved.
6 All patients enrolled were children 12 years of age or younger.
7 Significantly different (p
5 0.001) in favor of ceftazidime plus metronidazole.
8 Cultures from four of nine patients with superficial surgical site “infections” revealed no growth.
9 Five patients in the clinically evaluable population had soft tissue infections.
10 Significantly different (p
5 0.006) in favor of cefoperazone/sulbactam.

1 Aminoglycoside

[109]
Yellin,
1993

[108]
Collins,
1998

[104]
Solomkin,
in press

Ertapenem
1 g qd85

NR

NR

4%14

6%14

100%

100%

NR90

59%

61%

1

2

4

No

No

Yes2

No

Probably
not

Yes
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12 After

Three patients in the clinically evaluable population had soft tissue infections.
the initial dose, subsequent tobramycin dosing was based on pharmacokinetic calculations and serum drug concentrations.
13 Success rates were calculated after excluding patients with indeterminate outcomes.
14 Mortality rates were based on all patients enrolled in the study.
15 Use of vancomycin was permitted for patients thought to have resistant Gram-positive organisms.
16 Significantly different (p 5 0.04) in favor of imipenem/cilastatin.
17 Median APACHE II scores were provided for different diagnoses.
18 Pediatric dosing.
19 Patients enrolled included children 2 years of age or older and adult patients.
20 Children 10 years of age and younger received the higher gentamicin dose.
21 All patients enrolled were children 18 years of age and younger.
22 Higher doses and/or shorter dosing intervals were used for patients with serious or life-threatening infections.
23 Use of vancomycin, nafcillin, or metronidazole was permitted for patients with Gram-positive organisms resistant to clindamycin.
24 Pediatric doses were adjusted according to weight.
25 Patients enrolled included children 3 years of age or older and adult patients.
26 Significantly different (p
5 0.02) in favor of ceftriaxone plus metronidazole.
27 Dosage not reported.
28 All patients enrolled were children between 2 and 15 years of age.
29 Dosage was modified according to renal function.
30 Patients with superficial surgical site infections were not necessarily considered failures.
31 Only an intention-to-treat analysis was reported.
32 Failures included patients who received additional antibiotics for any reason, even if unrelated to the intra-abdominal infection.
33 Mortality rate includes patients who died more than 35 days after completion of therapy.
34 Percentages of patients with appendicitis were based on all patients enrolled in the study.
35 All patients enrolled were between 1 and 16 years of age.
36 Patients were enrolled for nosocomial pneumonia, sepsis, or severe diffuse peritonitis.
37 Success rates refer only to clinically evaluable patients with peritonitis.
38 The mortality rate was not reported separately for patients with peritonitis. The mortality rate due to infection in all enrolled patients was 13% in patients treated
with imipenem/cilastatin and 9% in patients treated with imipenem/cilastatin plus netilmicin.
39 The mean APACHE II score for patients with peritonitis was not reported. The mean APACHE II scores for all enrolled patients were 9.8 for patients treated
with imipenem/cilastatin and 9.6 for patients treated with imipenem/cilastatin plus netilmicin.
40 Patients with peritonitis in the imipenem/cilastatin group had higher APACHE II scores.
41 After 3 days of treatment, oral ciprofloxacin (500–750 bid) could be substituted for intravenous ciprofloxacin.
42 Gentamicin was discontinued after 3 days in 51% of patients whose organisms were sensitive to cefotaxime.
43 Significantly different (p 5 0.02) in favor of ciprofloxacin plus metronidazole.
44 Netilmicin could be administered intramuscularly or intravenously.
45 Oral administration of metronidazole was permitted.
46 Metronidazole was not given to 28% of patients receiving once daily netilmicin and to 32% of patients receiving thrice daily netilmicin.
47 One patient in the clinically evaluable population had a soft tissue infection.
48 Oral tinidazole (1 g qd) could be substituted for intravenous tinidazole.
49 Patients enrolled included children 12 years of age and older and adults.
50 Significantly different (p 5 0.001) in favor of piperacillin/tazobactam.
51 Significantly different (p
5 0.02) in favor of piperacillin/tazobactam.
52 Patients were enrolled for nosocomial pneumonia or peritonitis.
53 Of the 159 clinically evaluable patients with peritonitis, 29 did not undergo a surgical procedure.
54 Only mortality attributable to infection was reported.
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56 After

Success rates were calculated after excluding patients with incomplete follow-up or indeterminate outcomes.
2 days, patients could be switched to blinded therapy with oral ciprofloxacin and oral metronidazole. Dosages not reported.
57 Significantly different (p 5 0.047) in favor of ciprofloxacin plus metronidazole.
58 Amikacin, 15 mg/kg/day, could be added at the investigator’s discretion for additional coverage of
Pseudomonas.
59 Twelve patients randomized to receive aspoxicillin and 13 patients randomized to receive piperacillin were given an additional antimicrobial, usually an aminoglycoside.
60 After the start of therapy, patients could be switched to oral ciprofloxacin 750 mg q12h plus oral metronidazole 200 mg q12h.
61 Contains 1 g of amoxacillin and 200 mg of clavulanic acid.
62 After the start of therapy, patients could be switched to oral amoxacillin/clavulanic acid 875 mg q8h plus metronidazole 200 mg q12h.
63 After the start of therapy, patients could be switched to oral trovafloxacin, 200 mg qd, at the investigator’s discretion.
64 After the start of therapy, patients could be switched to oral amoxacillin/clavulanic acid 50 mg q8h.
65 All patients had diagnoses consistent with IDSA criteria, but patients with negative peritoneal cultures were considered clinically evaluable.
66 The source of the infection was not fully explained in patients having bacteremia associated with an appendiceal or colonic perforation.
67 Dosage of cefmetazole could be increased to 8 g per day at the investigator’s discretion.
68 Dosage of cefoxitin could be increased to 12 g per day at the investigator’s discretion.
69 The numbers of clinically evaluable patients were not reported for the two study groups.
70 The numbers of successfully treated patients were not reported for the two study groups.
71 The authors stated that there were no statistically significant differences in success rates comparing cefmetazole and cefoxitin.
72 Significantly different (p
5 0.008) in favor of cefotaxime plus metronidazole.
73 At later, follow-up, success rates were 98% for 54 patients treated with meropenem, and 97% for 64 patients treated with cefotaxime plus metronidazole.
74 Significantly different (p 5 0.008) in favor of meropenem.
75 Mortality rates were reported at the end of therapy for all patients enrolled in the study. During subsequent follow-up, mortality increased to 6% for patients treated
with meropenem and to 11% for patients treated with cefotaxime plus metronidazole.
76 Patients were enrolled for intra-abdominal infections and other indications.
77 These values represent the numbers of clinically evaluable patients who had intra-abdominal infections. Some patients may have had other infections as well.
78 Success rates for clinically evaluable patients with intra-abdominal infections were estimated from data provided in the article. Success rates include patients reported as cured or improved.
79 Significantly different (p
5 0.02) in favor of cefepime plus metronidazole. After adjustment for differences in prognostic factors between the two groups, the difference was no longer significant (p 5 0.06).
80 Only wound infections associated with fever were reported as failures.
81 Mortality rates were based on the ITT populations. The difference in mortality significantly favored patients treated with cefepime plus metronidazole (p
5 0.03).
82 Mean APACHE II scores were significantly higher among patients treated with imipenem/cilastatin.
83 The percentage of patients with appendicitis was significantly higher in the imipenem/cilastatin group.
84 Mean APACHE II scores were significantly higher among patients treated with aztreonam plus clindamycin.
85 Use of vancomycin was permitted for patients with methicillin resistant Staphylococcus aureus or enterococcal infections; the use of antifungal therapy was permitted.
86 After 3 days, patients could be switched to blinded therapy with oral ciprofloxacin, 500 mg q12h plus oral metronidazole, 500 mg q6h. Patients in the other arms of
the study received intravenous antimicrobials only.
87 Significantly different (p 5 0.014) in favor of meropenem.
88 A surgical procedure was not performed in 46% of patients in the meropenem group and in 28% of patients in the imipenem/cilastatin group.
89 All patients enrolled were children 3 months to 11 years of age.
90 Intra-abdominal infections were primarily due to perforated appendicitis.
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tions. Recommendations regarding higherrisk patients will be discussed in the subsequent section.
Summary of findings
Aminoglycosides. The combination of an
aminoglycoside and an antianaerobic agent
was considered the mainstay of antimicrobial
therapy for intra-abdominal infections until
newer agents were found to be equally effective. Thus, this combination was extensively
used as a comparator in many trials of newer
antimicrobials. The committee reviewed 27
studies, including three published prior to
1990, in which the combination of an aminoglycoside plus an antianaerobic agent was compared to other regimens [40–66]. One additional study compared the efficacy of two
different aminoglycosides in combination with
an antianaerobic agent [67]. There were also
three studies in which an aminoglycoside was
tested in combination with other agents having
extended spectrum gram-negative coverage
[68–70]. These latter studies will be considered
more fully in the subsequent discussion of therapy for higher risk patients with intra-abdominal infections.
A total of 1,786 clinically evaluable patients
were treated with aminoglycoside-based regimens in the 28 studies reviewed. The aminoglycosides tested included gentamicin, tobramycin, netilmicin, amikacin, and isepamicin.
Either clindamycin or metronidazole were
utilized as the antianaerobic agents in all
studies, and in one study [65] ornidazole was
also tested. This regimen was compared to a
variety of other single agents or combination
regimens, including an extended-spectrum
penicillin alone or combined with a beta-lactamase inhibitor [41,42,49,56,60,61,65], a second-generation cephalosporin with intrinsic
anaerobic coverage [40,53,59,66], a third- or
fourth-generation cephalosporin in combination with an antianaerobic agent or a betalactamase inhibitor [43,44,46,50,52,55,58,65]
aztreonam plus clindamycin [51,57], a carbapenem alone [47,48,54,62-64], or the combination of a fluoroquinolone plus metronidazole [45]. In one study, the aminoglycosides,
isepamicin and amikacin were compared [67].
In six of these studies, antibiotics effective
against Enterococcus or other gram-positive
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organisms were permitted or required along
with the aminoglycoside and the antianaerobic agent [48,50–52,60,65].
Many of these 28 studies involved patients
with relatively low–acuity infections. Nine studies enrolled patients with appendicitis only
[41,43,49,50,53,55,59,63,65]. Mortality among
aminoglycoside-treated patients was greater
than 5% in only four of these studies
[40,47,48,58]. Many of these studies were published toward the beginning of the decade, and
tended to be of relatively lower quality than later
studies.
Success rates using aminoglycoside-based
regimens ranged from 70% to 100% in these
studies except for one trial in which only the results of an ITT analysis were presented [58]. The
overall success rate was 86% for all 1,786 clinically evaluable patients who received aminoglycosides. The individual and overall success
rates were comparable to those obtained with
other antimicrobial regimens used for treating
intra-abdominal infections. Most of the studies
demonstrated no significant differences in patient outcome between the aminoglycosidebased and comparator regimens, but in five
studies the differences in success rates were statistically significant. Success rates were lower
with an aminoglycoside-based regimen compared to a third-generation cephalosporin plus
an antianaerobe in two studies, compared to a
third-generation cephalosporin/beta-lactamase
inhibitor combination in one study, and compared to carbapenem in one study [43,44,48,52].
In two of these studies, the higher failure rates
observed in aminoglycoside-treated patients
were due entirely to an increase in superficial
surgical site infections [43,52]. In contrast to
these studies, an earlier study found an aminoglycoside-based regimen to be superior to ampicillin/sulbactam for patients with complicated
appendicitis [41].
In analyzing the results of their trial comparing imipenem/cilastatin with tobramycin plus
clindamycin, Solomkin et al. [48] suggested that
a delay in achieving therapeutic tobramycin
concentrations contributed to the higher failure
rate observed in patients who received the
aminoglycoside-based regimen. Among the
other studies that described lower success rates
with aminoglycoside-based therapy, one did
not report any monitoring of serum aminogly-
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coside concentrations [52], and the other two
did not comment on the time required to
achieve therapeutic aminoglycoside concentrations [43,44]. Thus, if aminoglycoside-based
regimens are utilized, it would seem prudent to
direct attention toward prompt attainment of
therapeutic concentrations of these agents, perhaps by using a once-daily dosing strategy.
Once-daily administration of aminoglycosides is an alternative that simplifies the use of
these agents, and potentially avoids problems of
underdosing. In a large meta-analysis of patients
treated with aminoglycosides for any indication,
once-daily aminoglycoside dosing was associated with similar efficacy and possibly decreased toxicity compared to multiple daily dose
regimens [71]. Two prospective randomized
controlled trials have compared once-daily with
multiple daily dose regimens of netilmicin in patients with intra-abdominal infections [72,73].
Success rates were greater than 90% in the treatment arms of both studies, and no significant
differences in therapeutic efficacy or toxicity
were detected. However, many of the evaluable
patients in these studies had relatively mild infections, and it is uncertain if these results apply to a more severely ill population of patients
receiving aminoglycosides.
Based on these studies using aminoglycosidebased regimens, the Committee continues to include the combination of an aminoglycoside
with an antianaerobic agent in the list of recommended agents for the treatment of intra-abdominal infections. However, given the equivalent performance of other regimens and the
nephrotoxicity and ototoxicity of aminoglycosides, these drugs should not necessarily be considered first-line agents for therapy. They may
be of greater use for patients who have failed
therapy with other agents or for patients with
severe allergic reactions to other antimicrobials.
Penicillin/beta-lactamase inhibitor combinations.
In the previous guidelines [1], ticarcillin/clavulanic acid was the only recommended agent in
this class for the treatment of patients with
intra-abdominal infections. However, ampicillin/sulbactam has been employed frequently
for this indication. The Committee identified at
least three prospective randomized controlled
trials that evaluated use of this agent, two of
which were published prior to 1990. In these
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studies, ampicillin/sulbactam was compared
against gentamicin plus clindamycin [41,42] or
cefoxitin [74]. One study enrolled only patients
with complicated appendicitis [41]. Mortality
in all studies appeared to be low.
A total of 209 clinically evaluable patients received ampicillin/sulbactam in these trials. The
reported success rates were 86–88% in the individual trials; among all 209 patients who received ampicillin/sulbactam, the success rate
was 87%. In one trial, limited to patients with
complicated appendicitis [41], the failure rate
was significantly higher with ampicillin/sulbactam than with gentamicin and clindamycin.
However, one-half of these failures were due
to superficial surgical site infections. In addition, there was an imbalance in randomization,
such that fewer patients with gangrenous appendicitis and more patients with perforated
appendicitis received ampicillin/sulbactam
than received gentamicin plus clindamycin. In
the other two studies, there were no significant
differences in therapeutic efficacy comparing
ampicillin/sulbactam to the other agents. Based
on these limited data and the relatively widespread clinical use of this agent, the Committee
has included ampicillin/sulbactam in the list of
acceptable single agents for the treatment of patients with intra-abdominal infections.
The use of ticarcillin/clavulanic acid for the
treatment of intra-abdominal infections was
described further in three trials published between 1990 and 2000 [49,60,75]. This agent was
compared to gentamicin-containing regimens
in two studies [49,60] and to imipenem/cilastatin in one [75]. Two of these trials enrolled
only patients with complicated appendicitis
[49,75], and mortality in all studies appeared to
be low. Overall, these trials included 324 clinically evaluable patients treated with ticarcillin/clavulanic acid. Success rates in these
trials ranged from 86% to 97%. The overall success rate among all patients treated with ticarcillin/clavulanic acid was 88%. There were no
statistically significant differences in outcome
in any of the studies. The Committee continues
to recommend ticarcillin/clavulanic acid for
antimicrobial therapy of intra-abdominal infections.
The use of piperacillin/tazobactam for treatment of patients with intra-abdominal infections
was examined in eight trials published over the
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past decade [56,61,76-81], and the use of
piperacillin alone was evaluated in another
three [65,82,83]. Comparator regimens included
an aminoglycoside plus an antianaerobic agent
[56,61,65], imipenem/cilastatin [76–78], cefuroxime plus metronidazole [79,82], a third-generation cephalosporin plus an antianaerobic agent
[65,81], ciprofloxacin plus metronidazole [80],
and another extended-range penicillin, aspoxicillin [83]. Only one of these trials [65] was restricted to patients with appendicitis. Mortality
was greater than 5% in two trials [81,82].
In these studies, 571 clinically evaluable patients were treated with piperacillin/tazobactam, and an additional 141 patients were
treated with piperacillin alone. Success rates
with piperacillin/tazobactam or piperacillin
alone ranged from 63% to 98% in individual trials, and the overall success rate for all clinically
evaluable patients was 85%. Success rates were
equivalent to the comparators in all trials except two. In one trial, piperacillin/tazobactam
appeared to be superior to imipenem/cilastatin
[76]. However, patients treated with the carbapenem had an unexpectedly low success rate
compared to that observed in other trials with
this agent [84]. In another study, treatment with
piperacillin/tazobactam appeared to be less efficacious than treatment with ciprofloxacin
plus metronidazole when the analysis was
based on clinically evaluable patients, but this
difference was not statistically significant in a
modified ITT analysis [80]. Based on these data,
the Committee has included piperacillin/
tazobactam in the list of recommended regimens for the treatment of patients with intraabdominal infections. The use of piperacillin
alone also appears to be acceptable for the treatment of these patients, but the use of
piperacillin alone seems to have been greatly
curtailed since piperacillin/tazobactam became available. The Committee therefore has
made no separate recommendation with regard to the use of piperacillin alone.
The extended spectrum penicillin/beta lactamase regimens described here, particularly
ampicillin/sulbactam and piperacillin/tazobactam, cover most isolates of Enterococcus recovered from patients with community-acquired
intra-abdominal infections. In three studies
evaluating ampicillin/sulbactam [41,42,74] and
six studies evaluating piperacillin/tazobactam
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or piperacillin alone [56,61,79–82], the comparator regimen would not have had similar
coverage. The trial of Röhrborn et al. [81] was
designed specifically to study the need for enterococcal coverage in patients treated for community-acquired intra-abdominal infections.
None of these trials demonstrated any advantage to the extended spectrum penicillin/betalactamase regimen. Thus, these data suggest
that routine coverage of Enterococcus is not necessary for most patients with community-acquired intra-abdominal infections.
In two studies, oral amoxicillin/clavulanic
acid was used to complete a course of intravenous
amoxacillin/clavulanic acid
or
imipenem/cilastatin [85,86]. Utilization of the
oral agent was at the investigator’s discretion,
however, and not according to a specific protocol. A prospective trial of an obligatory intravenous regimen compared to one permitting
conversion to oral amoxicillin/clavulanic acid
has not been conducted. Based on the limited
evidence from these two trials, the use of oral
amoxicillin/clavulanic acid to complete a
course of intravenous antimicrobials appears to
be an acceptable option for selected patients
with intra-abdominal infections who are able
to tolerate an oral diet.
Cephalosporins. In the previous guidelines,
Bohnen et al. [1] recommended second-generation cephalosporins with anaerobic coverage,
specifically cefoxitin, cefotetan, and cefmetazole,
as acceptable monotherapy for the treatment of
patients with intra-abdominal infections of mild
to moderate severity. The use of these agents has
been examined in at least eight prospective randomized controlled trials, four of which have
been published since 1990 [40,53,59,74,87–90].
Two of these trials [53,59] were restricted to patients with appendicitis. In only one study was
mortality greater than 5% [40].
Cefoxitin was compared to an aminoglycoside plus clindamycin [40,53], ampicillin/sulbactam [74], cefotetan [87], cefmetazole [89], or
imipenem/cilastatin [90] in six studies enrolling an estimated 337 clinically evaluable patients. Reported success rates ranged from 78%
to 97% in these trials. The overall success rate
among all cefoxitin-treated patients was 85%.
Cefotetan was compared to amikacin plus clindamycin [59], cefoxitin [87], or moxalactam [88]
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in 244 clinically evaluable patients. Success
rates in the cefotetan-treated patients ranged
from 90% to 98% in these three trials. The success rate among all patients treated with cefotetan was 95%. Among clinically evaluable
patients who received either cefoxitin or cefotetan, the overall success rate was 89%. There
were no statistically significant differences in
outcome in any of the trials which utilized cefoxitin or cefotetan.
The Committee could identify only a single
prospective randomized controlled trial that
examined the use of cefmetazole for the treatment of patients with intra-abdominal infections [89]. This small study enrolled 52 patients
treated with cefmetazole and 27 treated with
cefoxitin. An overall success rate of 92% was
described, but the success rates using each
agent were not described unambiguously. The
authors stated that there were no statistically
significant differences in clinical outcome comparing cefmetazole to cefoxitin.
Based on these data, the Committee continues
to recommend cefoxitin and cefotetan as acceptable agents for the empiric treatment of patients with intra-abdominal infections. Although the spectrum of activity of cefmetazole
is similar to cefoxitin and cefotetan, the Committee does not believe that there is adequate evidence to make a specific recommendation with
respect to this agent, particularly since it has not
been widely used for treating patients with intra-abdominal infections following its initial
evaluation.
The efficacy of another second-generation
cephalosporin, cefuroxime, in combination
with metronidazole, was compared to that of
piperacillin/tazobactam [79], piperacillin alone
[82], or imipenem/cilastatin [91] in three clinical trials, including 281 clinically evaluable patients. None of these studies was restricted to
patients with appendicitis, and none had a mortality rate of greater than 5%. Cefuroxime plus
metronidazole was equivalent to the comparator in each study, with success rates ranging
from 64% to 91% in individual studies. The overall success rate was 87% for all clinically evaluable patients treated with this regimen. Based
on these data, the combination of cefuroxime
plus metronidazole has been added to the recommended list of regimens for the treatment of
patients with intra-abdominal infections.
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Bohnen et al. [1] included combinations of a
third-generation cephalosporin (cefotaxime,
ceftizoxime, ceftazidime, or ceftriaxone) with
an antianaerobic agent in their list of recommended regimens for the treatment of patients
with intra-abdominal infections. Since 1990,
additional trials of cefotaxime [50,81,92–94],
ceftazidime [43,46], and ceftriaxone [52,65,81],
have been published. The fourth-generation
cephalosporin, cefepime, was also evaluated in
two published trials [55,95]. Metronidazole
was the antianaerobic agent used along with
the cephalosporin in most of these trials
[43,52,55,81,92–95], although clindamycin was
used in two trials [46,50] and ornidazole in one
other [65]. The comparator regimens included
an aminoglycoside plus an antianaerobic agent
[43,46,50,52,55,65], an extended spectrum penicillin with or without a beta-lactamase inhibitor
or metronidazole [65,81], or a carbapenem [92–
95]. Four of these trials were restricted to patients with appendicitis [43,50,56,65]. Mortality
was greater than 5% in three trials, all of them
relatively recent [81,93,94].
In these eleven trials, 642 evaluable patients received the combination of a third- or fourthgeneration cephalosporin with an antianaerobic agent. Overall success rates using the
cephalosporin-based regimens ranged from 75%
to 100%, with the rate being 92% for all patients
treated with this regimen. In five of these trials,
success rates with the cephalosporin-based regimens differed significantly from those of the
comparators. In two of these trials, as indicated
previously, outcome was significantly better
with a cephalosporin-based regimen compared
to an aminoglycoside-based regimen [43,52]. In
two other trials, the cephalosporin-based regimen was significantly favored over a carbapenem [92,95], but the opposite was found in
one additional trial [93]. In the largest of these
trials [95], the combination of cefepime and
metronidazole appeared to be superior to
imipenem/cilastatin in an unadjusted analysis.
However, the authors noted that there was an
imbalance in randomization; patients who received imipenem/cilastatin had higher mean
APACHE II scores than patients who received
cefepime plus metronidazole. After using a multivariate analysis to adjust for differences in clinical risk factors, the statistical advantage in favor
of cefepime plus metronidazole was lost. In ad-
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dition, no statistically significant differences
were found in an ITT analysis.
Based on the aggregate data, the Committee
continues to include the combination of a thirdor fourth-generation cephalosporin with an antianaerobic agent in the list of recommended
agents for the treatment of patients with intraabdominal infections. The previous guidelines of
Bohnen et al. [1] included cefotaxime, ceftazidime, ceftriaxone, and ceftizoxime as acceptable third-generation cephalosporins, to which
the fourth-generation cephalosporin, cefepime,
can be added. It should be noted, however, that
the data in support of some of these individual
agents are limited, and no new publications
supporting the use of ceftizoxime were identified. Thus, it is uncertain if these agents are actually all of equivalent therapeutic efficacy.
Monobactams. Aztreonam plus clindamycin
was listed previously as an acceptable regimen
for the treatment of patients with intra-abdominal infections [1]. Three additional prospective
trials, including 177 clinically evaluable patients
treated with this regimen, have been published
since 1990 [51,57,96]. Aztreonam plus clindamycin was compared to an aminoglycoside
plus clindamycin in two studies [51,57] and to
imipenem/cilastatin in one [96]. None of these
trials was restricted to patients with appendicitis, and none had a mortality rate of greater than
5%. The success rates with aztreonam plus clindamycin ranged from 71% to 100% in the individual trials. The overall success rate was 84%
among all patients treated with this regimen.
There were no statistically significant differences between aztreonam plus clindamycin and
the comparators in any of the trials. The Committee continues to recommend this regimen for
the treatment of patients with intra-abdominal
infections.
Carbapenems. Imipenem/cilastatin was also included previously in the list of recommended
agents for the treatment of intra-abdominal infections [1]. In studies published between 1990
and 2000, both imipenem/cilastatin and another
carbapenem, meropenem, were evaluated extensively as single agents for the treatment of
patients with intra-abdominal infections. In 13
trials, imipenem/cilastatin was compared to
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agents in other antimicrobial classes [47,48,
54,75–78,86,90,91,95–97], and in six studies
meropenem was compared to other therapeutic
agents [62–64,92–94]. In five additional studies,
imipenem/cilastatin and meropenem were
compared with each other [98–102], and in one
study, imipenem/cilastatin was compared to
another carbapenem, biapenem [103].
In all, imipenem/cilastatin was used in 1,496
clinically evaluable patients, compared against
an aminoglycoside plus an antianaerobic agent
[47,48,54], ticarcillin/clavulanic acid [75],
piperacillin/tazobactam [76–78], cefoxitin [90],
cefuroxime [91] or cefepime [95] plus metronidazole, aztreonam plus clindamycin [96],
ciprofloxacin plus metronidazole [97], alatrofloxacin [86], meropenem [98–102], or biapenem [103]. Completion of therapy with oral
amoxacillin/clavulanic acid was permitted in
one study [86]. Only one of these studies [75]
was limited to patients with an appendiceal
source of infection. Mortality rates greater than
5% were observed in six of the studies comparing imipenem/cilastatin against other agents
[47,48,76,91,95,97] and in one study comparing
imipenem/cilastatin with meropenem [102].
Success rates using imipenem/cilastatin
ranged from 69% to 100% in the individual trials. The success rate among all 1,496 clinically
evaluable patients who received imipenem/
cilastatin was 87%. In three studies [48,76,95],
discussed previously, statistically significant
differences in success rates were observed between imipenem/cilastatin and the other
agents. One of these trials favored imipenem/
cilastatin [48] and two favored the comparators [76,95]. There were no statistically significant differences in outcome in any of the
studies comparing imipenem/cilastatin and
meropenem.
Meropenem was tested in 768 clinically evaluable patients, and it was compared against tobramycin plus clindamycin [62–64], cefotaxime
plus metronidazole [92–94], and imipenem/
cilastatin [98–102]. One of these studies [63] included only patients with appendicitis. Mortality rates were greater than 5% in three studies
[93,94,102]. In individual trials, the clinical success rates using meropenem ranged from 91%
to 100%. The success rate in all patients treated
with meropenem was 95%. One trial comparing
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meropenem to cefotaxime plus metronidazole
found the success rate to be significantly higher
with meropenem [93], but the opposite was
found in another trial [92].
A meta-analysis by Chang and Wilson [84]
further supported the use of carbapenems for
the treatment of patients with intra-abdominal
infections. This study summarized the results
of ten trials comparing imipenem/cilastatin or
meropenem against non-carbapenem comparators. Overall, there were no significant differences in success rates comparing the carbapenems against other regimens. There were
also no significant differences in outcome in
separate assessments of imipenem/cilastatin
and meropenem against their respective comparators. Based on this large body of evidence,
the Committee continues to recommend
imipenem/cilastatin for the treatment of patients with intra-abdominal infections, and has
added meropenem to the list of acceptable
agents.
As with the extended spectrum penicillin/
beta lactamase inhibitor combinations, both
imipenem/cilastatin and meropenem cover
routine isolates of Enterococcus faecalis. In many
of the studies cited above, the non-carbapenem
comparator would not have been expected
to provide reliable enterococcal coverage
[47,48,54,62–64,90–97]. However, there was no
evidence that the enterococcal coverage provided by the carbapenems improved clinical
outcome in any of these trials. These data, along
with the data from studies of extended spectrum penicillin/beta-lactamase inhibitor combinations, support the conclusion that routine
coverage of Enterococcus is unnecessary for
most patients with community-acquired intraabdominal infections.
Recently, a newer carbapenem, ertapenem,
was tested against piperacillin/tazobactam in a
large prospective randomized controlled trial
reported at the Annual Meeting of the SIS in
2001 [104]. Overall, 203 clinically evaluable patients were treated with ertapenem, of whom
61% had perforated appendicitis. The mortality
rate in this study was 6%. The success rate in patients treated with ertapenem was 87%, which
was equivalent to the 81% success rate observed
in patients treated with piperacillin/tazobactam. Based on the data from this large trial, the
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Committee has added ertapenem to the list of
acceptable therapeutic agents for the treatment
of patients with intra-abdominal infections.
However, clinical experience with this agent is
limited at present, so its overall usefulness for
this indication has yet to be defined fully.
Fluoroquinolones. The role of fluoroquinolones
in treating patients with intra-abdominal infections was investigated increasingly over the
past decade. Four trials compared the combination of ciprofloxacin plus metronidazole with
amoxacillin/clavulanic acid plus metronidazole [85]; piperacillin/tazobactam [80]; cefotaxime, gentamicin, and metronidazole [69]; or
imipenem/cilastatin [97]. None of these studies
was restricted to patients with appendicitis.
Mortality rates over 5% were observed in three
of the four trials [69,80,97].
These four studies included 429 clinically
evaluable patients who received ciprofloxacin
plus metronidazole. Success rates using this
regimen ranged from 74% to 97%, and the success rate among all clinically evaluable patients
was 82%. In two trials, there was a statistically
significant difference in success rates favoring
the ciprofloxacin plus metronidazole regimen
[69,80], although this advantage was not observed in an ITT analysis performed as part of
one trial [80].
In a carefully designed study, Solomkin et
al. [97] examined the efficacy of oral ciprofloxacin and metronidazole in patients with intra-abdominal infections. In this study, there
were two separate arms that involved treatment with ciprofloxacin plus metronidazole. In
one arm, patients received only intravenous
ciprofloxacin and metronidazole, whereas in
the other, patients could receive blinded oral
therapy with the same agents after 3 days of intravenous therapy. Approximately 47% of the
patients in this trial were switched to oral medications or placebos. Success rates were similar
among patients who received only intravenous
therapy and patients who were allowed to receive oral therapy.
Overall, the Committee believes that the evidence justifies inclusion of the regimen of
ciprofloxacin plus metronidazole in the list of
recommended agents for the treatment of intra-abdominal infections. There is also reason-
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able evidence that oral ciprofloxacin and
metronidazole can be used to complete an initial intravenous course of these agents for patients able to tolerate oral medications.
The role of other fluoroquinolones for the
treatment of intra-abdominal infections remains to be determined. There is particular interest in newer agents that are active against
anaerobic as well as aerobic gram-negative organisms, and thus could be used as single
agents for these infections. In one large study,
a regimen using intravenous alatrofloxacin followed by oral trovafloxacin was found comparable to a regimen of imipenem/cilastatin followed by oral amoxicillin/clavulanic acid [86].
However, because of its hepatic toxicity, use of
alatrofloxacin and trovafloxacin was subsequently curtailed sharply, and this regimen
cannot be recommended at present. Additional
fluoroquinolones, such as moxifloxacin and
others still in clinical development, are currently being tested as monotherapy for patients
with intra-abdominal infections. Such agents
may provide additional therapeutic alternatives for these patients in the future.
Antianaerobic agents. The previous guidelines
recommended clindamycin and metronidazole
as acceptable antianaerobic agents in combination regimens for the treatment of patients with
intra-abdominal infections. These guidelines
did not recommend the use of chloramphenicol because of its risk of side effects [1]. The
Committee uncovered very little recent data
with which to evaluate further these recommendations.
In several studies, a trend toward increasing
in vitro resistance of B. fragilis and other anaerobes to several antianaerobic agents was observed. However, this did not appear to be occurring with metronidazole [105–107]. This led
some authors to question the use of antimicrobials such as cefoxitin and clindamycin for
patients with intra-abdominal infections [107].
Although an occasional clinical failure in
prospective trials has been attributed to resistant anaerobic bacteria, the overwhelming
majority of prospective trials provide little indication that success rates are influenced significantly by the antianaerobic component of
the regimen, as long as anaerobic coverage is
present. Thus, the clinical relevance of the

MAZUSKI ET AL.

changing resistance patterns of anaerobic organisms remains uncertain.
A few reports published between 1990 and
2000 evaluated the efficacy of the antianaerobic agents used to treat patients with intra-abdominal infections. One small prospective
study compared 75 pediatric patients who received a regimen of ampicillin/sulbactam and
gentamicin against 39 similar patients who received a regimen of ampicillin, gentamicin and
clindamycin [108]. Success rates for both study
groups were 97%, suggesting that ampicillin/sulbactam had adequate anaerobic efficacy. Another prospective trial randomized patients with perforated appendicitis to receive
clindamycin, 900 mg given every 8 h or clindamycin, 600 mg given every 6 h; all patients
also received gentamicin to cover aerobic/facultative anaerobic gram-negative organisms
[109]. Success rates were 93% and 91% in 80 and
46 clinically evaluable patients, respectively. In
some studies, a lower dose of clindamycin, 600
mg given every 8 h, has been used. Rovers et
al. [110] compared patient outcomes in three series that used this dosing regimen with outcomes in three other series that used a higher
dose of 900 mg q8h. These authors concluded
that the lower dose of clindamycin was less efficacious for the treatment of patients with intra-abdominal infections. However, since none
of the studies included in the analysis by these
authors directly compared these two regimens,
this conclusion seems questionable.
Overall, the Committee does not believe that
the available data justify any change in the previous recommendations regarding antianaerobic agents. Thus, clindamycin or metronidazole
continue to be recommended as acceptable antianaerobic components of combination regimens used for the treatment of patients with
intra-abdominal infections.
Selection of antimicrobial agents. The recommended antimicrobial agents for the treatment
of patients with intra-abdominal infections are
listed in Table 12. As discussed previously, the
Committee did not designate preferred or firstline regimens, because the available evidence
did not prove that any specific regimen was superior. Thus, for the treatment of most patients,
particularly those with mild-to-moderate community-acquired infections, selection of spe-
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TABLE 12. RECOMMENDED ANTIMICROBIAL REGIMENS
FOR INTRA -ABDOMINAL INFECTIONS
Single agents
Ampicillin/sulbactam
Cefotetan
Cefoxitin
Ertapenem
Imipenem/cilastatin
Meropenem
Piperacillin/tazobactam
Ticarcillin/clavulanic acid
Combination regimens
Aminoglycoside (amikacin, gentamicin, netilmicin,
tobramycin,) plus antianaerobe (clindamycin or
metronidazole)
Aztreonam plus clindamycin
Cefuroxime plus metronidazole
Ciprofloxacin plus metronidazole
Third/fourth-generation cephalosporin (cefepime,
cefotaxime, ceftazidime, ceftizoxime, ceftriaxone)
plus antianaerobe

cific antimicrobials must be based on criteria
other than clinical efficacy.
One property that could potentially guide selection of an initial empiric regimen is the activity of the antimicrobial agents against the
common bacterial organisms that cause intraabdominal infections. In actuality, all the recommended regimens are active against the typical aerobic and anaerobic pathogens observed
in patients with community-acquired infections.
The various antimicrobial agents differ with respect to their coverage of Enterococcus and their
breadth of gram-negative coverage.
As discussed previously, there is little indication that routine enterococcal coverage is necessary for most patients with community-acquired
intra-abdominal infections, therefore this should
not be a consideration. With regard to activity
against gram-negative organisms, some agents
such as second-generation cephalosporins or
ampicillin/sulbactam provide less coverage of
organisms such as Enterobacter and Pseudomonas
than do broader-spectrum agents in their
classes. Nonetheless, these antimicrobials have
generally performed as well as others in clinical
trials. Thus, the expanded gram-negative spectrum of many recommended antimicrobial
agents is not necessarily advantageous for patients with community-acquired intra-abdominal infections, who are at relatively low risk for
failure. In fact, since one of the guiding principles of antimicrobial therapy is to use an agent
with a narrower spectrum of activity when pos-
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sible, it might even be preferable to use an
agent such as cefoxitin, cefotetan, ampicillin/
sulbactam, or ticarcillin/clavulanate for the initial empiric treatment of lower-risk patients
with intra-abdominal infections. However, this
would not apply to patients likely to harbor
more resistant organisms, such as those already
in health care institutions or those who have recently been treated with antimicrobial agents.
Another relevant consideration to the selection of specific antimicrobials for the treatment
of intra-abdominal infections is the toxicity of
different agents. Because of their narrow therapeutic ranges and associated problems of ototoxicity and nephrotoxicity, aminoglycosides
are generally considered higher-risk agents.
Fear of toxicity may actually lead to underdosing of these agents, and thereby result in
therapeutic failure [48]. It would seem reasonable to use these agents primarily for patients
with allergies to other antimicrobial agents or
when necessary to treat resistant organisms.
Cost considerations could play a role in the
selection of the initial empiric antimicrobial
therapy. However, determining the actual costs
of different regimens is problematic. The acquisition costs of different antimicrobial agents
may be quite specific to a particular institution,
and differ substantially from national averages.
Costs of administration may add appreciably
to acquisition costs, but are difficult to estimate.
These may differ substantially for different regimens according to how many antimicrobial
doses must be given. In addition, the relatively
low acquisition costs of certain agents, such as
aminoglycosides, may be offset by costs incurred with laboratory monitoring. Finally, the
use of oral antimicrobials might allow for outpatient therapy, and thereby substantially decrease overall costs of treatment, notwithstanding the expense of the antimicrobial
agents themselves.
An additional issue related to the use of antimicrobials for intra-abdominal infections is
whether or not to alter the initial empiric regimen according to the results of intraoperative
cultures. There is substantial controversy regarding the usefulness of intraoperative cultures for most patients with intra-abdominal
infections, particularly those with communityacquired infections. Several authors believe
that the routine use of such cultures is unwar-
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ranted [111,112], while others still advocate
their use [90]. If peritoneal cultures are obtained, however, it is common for the final results to reveal one or more organisms resistant
to the initial empiric antimicrobial regimen.
The consensus of the Committee is that if the
patient is showing an adequate clinical response, there is little justification for changing
antimicrobial agents on the basis of culture results alone. Although this approach might be
considered in a patient who is not showing
signs of clinical improvement, there is also a
real possibility that such a patient has either a
persistent intra-abdominal infection requiring
further efforts at source control, or a nosocomial infection outside the abdomen requiring
different types of antimicrobials altogether.
Under either of these circumstances, alteration
of the antimicrobial regimen based on the intraoperative culture results may not be successful in treating the patient. The guidelines

TABLE 13. GUIDELINES

FOR

developed regarding the use of antimicrobial
regimens for the treatment of patients with intra-abdominal infections are listed in Table 13.
ANTIMICROBIAL THERAPY FOR THE
HIGHER-RISK PATIENT
Up to now, the guidelines have focused primarily on antimicrobial therapy for lower risk
patients with common community-acquired
intra-abdominal infections. Most of these patients are expected to make an uncomplicated
recovery following a primary source control
procedure and appropriate antimicrobial treatment. However, there are some patients with
intra-abdominal infections for whom an uncomplicated postoperative course seems less
likely. This impression may be due to the overwhelming nature of the infection itself, the patient’s severely limited physiological reserves,
or the failure of previous attempts at therapy.

ANTIMICROBIAL REGIMENS

FOR

INTRA -ABDOMINAL INFECTIONS

1. Antimicrobial regimens for intra-abdominal infections should cover common aerobic and anaerobic enteric
flora. The following antimicrobials or combinations of antimicrobials are effective for the treatment of intraabdominal infections. No regimen has been demonstrated to be superior to another (Level 1).
Single agents:
Ampicillin/sulbactam
Cefotetan
Cefoxitin
Ertapenem
Imipenem/cilastatin
Meropenem
Piperacillin/tazobactam
Ticarcillin/clavulanic acid
Combination regimens:
Aminoglycoside (amikacin, gentamicin, netilmicin, tobramycin) plus antianaerobe (clindamycin or
metronidazole)
Aztreonam plus clindamycin
Cefuroxime plus metronidazole
Ciprofloxacin plus metronidazole
Third/fourth-generation cephalosporin (cefepime, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone) plus
antianaerobe
2. For patients with mild-to-moderate community-acquired infections, agents having a narrower spectrum of
activity, such as antianaerobic cephalosporins, ampicillin-sulbactam, or ticarcillin-clavulanic acid are preferable to
more costly agents having broader coverage of gram-negative organisms and/or greater risk of toxicity (Level 3).
3. Completion of the antimicrobial course with oral forms of ciprofloxacin plus metronidazole (Level 2) or with
oral amoxacillin/clavulanic acid (Level 3) is acceptable in patients able to tolerate an oral diet.
4. Once-daily administration of aminoglycosides is the preferred dosing regimen for patients receiving these
agents for intra-abdominal infections. Careful attention should be paid to prompt attainment of therapeutic
antibiotic concentrations when aminoglycosides are used (Level 2).
5. Regimens providing enterococcal coverage are not routinely necessary in the treatment of most patients with
intra-abdominal infections (Level 2).
6. The routine use of intra-operative cultures is controversial. However, altering the antimicrobial regimen on the
basis of culture results does not improve outcome in patients having a satisfactory clinical response (Level 3).
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The selection of appropriate antimicrobial
therapy for higher-risk patients would be facilitated greatly by the identification of objective criteria for recognizing such patients. Several analyses, in fact, have identified specific
risk factors that predict mortality in patients
with intra-abdominal infections. However,
many of these risk factors are the same as those
that predict perioperative mortality in any patient undergoing a surgical procedure, whether
or not an intra-abdominal infection is present.
Such risk factors relate primarily to patients’
underlying comorbidities, such as preexisting
cardiac disease or other medical problems.
These risk factors are probably of little relevance in selecting specific antimicrobial regimens to be used in the treatment of higher risk
patients with intra-abdominal infection. However, risk factors for treatment failure rather
than postoperative mortality, particularly those
that pertain to the pathogenic organisms involved in the infection, might be more germane
to the selection of antimicrobial therapy for
higher risk patients. Unfortunately, relatively
few analyses have focused on the infection-related parameters that predict treatment failure.
Even if patients at higher risk for treatment
failure can be identified, the development of
specific recommendations is difficult because
relatively little Class I evidence pertains to
these higher-risk patients. As discussed previously, prospective randomized controlled trials comparing different antimicrobials primarily enrolled patients with community-acquired
intra-abdominal infections, such as perforated
appendicitis, who were likely at lower risk for
treatment failure and death. Many trials specifically excluded higher risk patients.
To characterize further the studies comprising the database, the Committee examined
mortality rates as crude indicators of the inclusion of higher-risk patients in the trials. Notably, three-quarters of the trials reported a
mortality of 5% or less, with a number reporting no mortality at all. This contrasts with mortality rates ranging from 17% to 32% in several
series evaluating risk factors for treatment failure and death in patients with intra-abdominal
infections [113–118], and a mortality rate of 6%
in an epidemiological survey that was broadly
representative of patients with intra-abdominal
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infections and included substantial numbers of
patients with complicated appendicitis [119].
The lower mortality rates found in clinical trials compared to broader surveys of patients
with intra-abdominal infections support the
conclusion that most patients enrolled in clinical trials were at relatively low risk for therapeutic failure, and that relatively few higherrisk patients were enrolled in most of these
studies.
Therefore, the Committee believes it is inappropriate to apply the results of most clinical
trials to higher-risk patients. There were a few
clinical trials that specifically focused on
higher-risk patients, and these trials did provide some Class I evidence suitable for developing recommendations. However, in the end,
many of these recommendations for higherrisk patients had to be based primarily on expert opinion.
Summary of findings
Identification of risk factors. For patients with
intra-abdominal infections, treatment failure
and death are likely related both to the severity of the infectious process as well as to the patient’s intrinsic physiological capacity to respond to that infection. In a number of studies
that utilized multivariate analyses to identify
risk factors for treatment failure or death
[95,113–117], this latter capacity proved to be
of paramount importance in determining the
likelihood of an adverse outcome. The independent risk factors identified in these studies
included higher APACHE II scores, advanced
age, malnutrition, hypoalbuminemia, hypocholesterolemia, the presence of medical conditions such as cardiovascular disease, renal
disease, and malignancy, and the use of corticosteroid medications (Table 14). Advanced
age and significant hypoalbuminemia were
identified as risk factors in more than one
study, but a higher APACHE II score was identified as an independent risk factor in all the
studies examined. Thus, the APACHE II score
appears to be the best predictor of treatment
failure or death in patients with intra-abdominal infections, a conclusion that has been
echoed by Ohmann and Hau [120].
Higher APACHE II scores primarily identify
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TABLE 14. INDEPENDE NT RISK FACTORS
Reference

FOR

MORTALITY

OR

TREATMENT FAILURE IDENTIFIED

Mortality

BY

MULTIVARIATE ANALYSES

Treatment failure

[95]
Barie, 1997

NR

APACHE II score
Prolonged prestudy length of hospitalization

[113]
Dellinger, 1985

APACHE II score
Malnutrition
Age

NR

[114]
Christou, 1993

APACHE II score
Hypoalbuminemia
NYHA functional class

APACHE II score
Hypoalbuminemia
Age

[115]
Bohnen, 1994

APACHE II score
Corticosteroid therapy

NR

[116]
Pucelli, 1996

APACHE II score
Mannheim peritonitis index
Hypoalbuminemia
Hypocholesterolemia
Preoperative organ impairment

NR

[117]
Wacha, 1999

APACHE II score
Unsuccessful operation
Age
Liver disease
Malignant disease
Renal disease

NR

patients with acute physiological changes induced by infection and chronically impaired
physiological reserves. It is unclear how the selection of antimicrobial therapy might be expected to impact clinical outcome in higher-risk
patients designated on this basis. It seems more
likely that the choice of antimicrobial therapy
would influence outcome if higher-risk patients were selected on the basis of the severity
of the intra-abdominal infection itself or, particularly, on the basis of the specific organisms
involved in the infection.
Traditionally, the source of the intra-abdominal infection was believed to influence the risk
of treatment failure and death, as exemplified
by the low mortality rates of patients with perforated appendicitis [113,114,116,119]. However, in multivariate analyses, the source of the
infection has not proved to predict outcome independently. The lower risk of treatment failure and death in patients with perforated appendicitis probably reflects the relatively
young age and lack of comorbid conditions
typical of patients with this disorder.
There is evidence, however, that the susceptibility patterns of the organisms involved in

the intra-abdominal infection influence the success or failure of empiric antimicrobial therapy.
In a trial by Christou et al. [90], all patients having at least one resistant organism isolated at
the time of initial intervention experienced
treatment failure. In another trial, Barie et al.
[95] found that a prolonged prestudy length of
hospitalization was an independent predictor
of failure. This risk factor may have identified
patients who had previous antimicrobial exposure or who had postoperative peritonitis, and
would therefore be more likely to harbor organisms resistant to commonly used antimicrobials. In a retrospective review of five antibiotic trials, Hopkins et al. [121] found that
the susceptibility of peritoneal isolates to the
initial empiric regimen also predicted treatment success or failure. Finally, Montavers et
al. [122] reached a similar conclusion based on
a retrospective review of patients with postoperative peritonitis, and showed by multivariate
analysis that the presence of organisms resistant to the empiric regimen was an independent predictor of mortality. It is important to
note that none of these studies provided direct
evidence that any specific antimicrobial regi-
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men would improve outcome in the higher-risk
patients defined by these criteria. However,
these results do suggest that a common feature
of higher-risk patients is the presence of resistant organisms. The Committee would speculate that many of these resistant organisms are
of nosocomial origin.
One final risk factor for failure that has been
increasingly emphasized in recent trials is an
inadequate initial source control procedure. An
unsuccessful operation was, in fact, found to be
a risk factor for death in the multivariate analysis carried out by Wacha et al. [117]. Clearly,
no antimicrobial regimen can be expected to be
successful if there is ongoing contamination or
an uncontrolled infectious source within the
abdomen.
Selection of antimicrobial regimens. Considering that higher-risk patients with intra-abdominal infections are more likely to fail because of
resistant organisms, it seems reasonable to recommend antimicrobial regimens with broader
coverage of gram-negative aerobic/facultatively anaerobic organisms for use in these patients. However, as discussed previously, this
recommendation was not made on the basis of
convincing Class I evidence demonstrating
that this approach improves outcome. In the
previous guidelines, Bohnen et al. [1] recommended imipenem/cilastatin, a third-generation cephalosporin plus an antianaerobic agent,
an aminoglycoside plus an antianaerobic
agent, or aztreonam plus clindamycin for the
treatment of patients with more serious infections. To this list, the Committee has added
piperacillin/tazobactam, meropenem, the
fourth-generation cephalosporin cefepime plus
an antianaerobic agent, and ciprofloxacin plus
metronidazole (Table 15). Depending on the likelihood of infection due to Pseudomonas in these
higher risk patients, the doses of some antimicrobial agents, such as piperacillin/tazobactam,
may need to be increased to provide adequate
anti-pseudomonal coverage. An aminoglycoside
plus an antianaerobic agent is still included in
the list of recommended regimens, but it is important that the aminoglycoside be dosed adequately to ensure rapid attainment of therapeutic serum concentrations in higher risk patients.
Further, these patients may be at increased risk
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TABLE 15. RECOMMENDED ANTIMICROBIAL REGIMENS
FOR HIGHER -RISK PATIENTS WITH
INTRA -ABDOMINAL INFECTIONS
Single agents
Imipenem/cilastatin
Meropenem
Piperacillin/tazobactam
Combination regimens
Aminoglycoside (amikacin, gentamicin, netilmicin,
tobramycin) plus an antianaerobe
Aztreonam plus clindamycin
Ciprofloxacin plus metronidazole
Third/fourth-generation cephalosporin (cefepime,
cefotaxime, ceftazidime, ceftizoxime, ceftriaxone)
plus an antianaerobe (clindamycin or
metronidazole)

for nephrotoxicity and ototoxicity due to these
agents.
Another potential approach to treatment of
higher risk-patients with intra-abdominal
infections is to utilize two agents effective
against gram-negative aerobic/facultative
anaerobic organisms. The usual combination is
an aminoglycoside plus an extended spectrum
beta-lactam antibiotic. This approach was
tested directly in several prospective randomized controlled trials. In the largest comparison, Dupont et al. [70] compared piperacillin/
tazobactam alone against the combination of
piperacillin/tazobactam with amikacin in patients with severe community-acquired intraabdominal infections and hospital-acquired intra-abdominal infections. The overall mortality
rate in this trial was 20%, attesting to the high
acuity of the patients enrolled. Although the
success rate with piperacillin/tazobactam
(51%) was lower than that observed in other
studies of intra-abdominal infections, it was
equivalent to that seen in the group receiving
combination therapy (51%). In another study,
imipenem/cilastatin alone was compared to
imipenem/cilastatin plus netilmicin in 78 patients with severe, diffuse peritonitis [68]. Patients with peritonitis due to appendicitis or
upper gastrointestinal perforations were excluded from this study. The success rate with
imipenem/cilastatin alone was 79% as compared to the success rate of 92% using
imipenem/cilastatin plus netilmicin. This difference in outcome was of borderline significance (p 5 0.09), and was likely explained by
an imbalance in the numbers of severely ill pa-
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tients in the two groups. Many more of the patients who received imipenem/cilastatin alone
had high APACHE II scores compared to those
who received the combination regimen. Finally, one additional study of 79 clinically
evaluable patients found that patients treated
with ciprofloxacin plus metronidazole had a
significantly better clinical outcome than patients treated with the combination of cefotaxime, gentamicin, and metronidazole [69].
Mortality was also relatively high in this study,
suggesting that a higher-risk group of patients
had been enrolled. Overall, these studies did
not demonstrate that the routine addition of an
aminoglycoside to another agent effective
against aerobic/facultative anaerobic gramnegative organisms improves outcome, and the
Committee recommends against this approach
in higher-risk patients with intra-abdominal infections.
Enterococcal coverage. Depending on the etiology and severity of the infection, Enterococcus
is isolated from 5–20% of patients with intraabdominal infections. Its importance as a
pathogen and the need for its routine treatment
remain controversial [74,80,81,90,95]. As described previously, prospective trials did not
demonstrate any improvement in outcome
comparing antimicrobial regimens that covered this organism with those that did not.
Therefore, the Committee did not recommend
routine use of regimens providing enterococcal
coverage for most patients with intra-abdominal infections.
However, it is not clear that this recommendation should be extrapolated to higher-risk
patients, particularly those with hospital-acquired infections. As emphasized repeatedly,
prospective trials have primarily enrolled less
severely ill patients. Further, the incidence of
enterococcal infections among enrolled patients has tended to be low. For instance, in the
study by Röhrborn et al. [81], which was designed specifically to test the need for routine
enterococcal coverage in patients with community-acquired intra-abdominal infections,
only 5% of the patients actually had Enterococcus isolated at the time of the initial laparotomy.
Enterococcal infections may be more com-
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mon in higher risk patients, and, as with other
resistant organisms, isolation of Enterococcus
may also identify patients at higher risk for
treatment failure. In the retrospective review
by Hopkins et al. [121], isolation of Group D
Streptococcus, presumably enterococci, was associated with the likelihood of failure, although
it was not clear that this was an independent
predictor of failure. However, in another multivariate analysis of data obtained from a
prospective trial, Burnett et al. [123] found that
the isolation of Enterococcus was indeed an independent predictor of failure. In this study of
330 patients, of whom 21% had positive cultures for Enterococcus, the failure rate was 28%
among patients who had this organism, but
was 14% among patients who did not. These
authors also found that patients at risk for enterococcal infections were those who were of
advanced age, had higher APACHE II scores,
had longer hospital lengths of stay prior to developing the infection, had a postoperative infection, or had a colonic or small bowel source
of infection. Enterococci did not tend to be isolated from patients with infections resulting
from appendicitis. Thus, the risk factors for
having enterococcal infections were quite similar to those that described higher-risk patients
in general.
Although there is no Class I evidence that
treatment of higher-risk patients with antimicrobials providing enterococcal coverage improves outcome, the Committee believes that
this may be a reasonable approach, given the
correlation that exists between enterococcal isolation and increased risk of treatment failure.
Thus, for higher-risk patients with intraabdominal infections, the Committee recommends that consideration be given to the use
of a regimen covering Enterococcus, particularly
when patients are likely to harbor this organism because of a previous failure of antimicrobial therapy. The choice of the specific antimicrobial regimen would depend in part on the
enterococcal resistance patterns specific to the
particular institution.
Treatment of Candida. Intra-abdominal infections due to fungal organisms, particularly
Candida albicans, primarily occur in higher-risk
patients. Many of these infections develop in
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postoperative patients, and almost all develop
in patients who have already been heavily
treated with broad-spectrum antibiotics [124].
Invasive candidal infections in the abdominal
cavity are associated with high mortality rates,
despite utilization of antifungal agents. Unfortunately, there are only limited prospective
data with which to evaluate different approaches to the prevention and management of
intra-abdominal infections due to Candida.
Early initiation of antifungal therapy appears
to be an important determinant of outcome in
patients with intra-abdominal candidal infections. Solomkin et al. [124] described 55 patients with Candida peritonitis, and noted a
progression of disease from infection of the
peritoneal cavity only, to colonization and infection of multiple sites, to the eventual development of candidemia and widespread, diffuse
candidiasis. Patients who did not receive antifungal therapy until they developed positive
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blood cultures were likely to fail treatment and
to die of the infection.
Although patients with Candida peritonitis
clearly have an established infection requiring
antifungal therapy, Candida is also isolated
from the peritoneal cultures of patients who are
colonized, but not infected with this organism.
Calandra et al. [125] examined a series of 49 patients with positive peritoneal cultures for Candida, to determine what clinical characteristics
predicted the need for antifungal therapy.
These authors found that patients with recurrent gastrointestinal perforations and those
with postoperative infections following surgical management of acute pancreatitis were at
high risk for having an invasive candidal infection requiring treatment. Patients with
heavy or increasing growth of Candida in semiquantitative cultures of peritoneal fluid were
also likely to need systemic antifungal therapy.
Based on these clinical findings, Eggiman et

TABLE 16. SUMMARY OF PROSPECTIVE RANDOMIZED CONTROLLED TRIALS OF ANTIFUNGAL
AGENTS FOR THE TREATMENT OF PATIENTS WITH INTRA -ABDOMINAL INFECTIONS

Reference

[126]
Eggiman,
1999

[127]
AbeleHorn,
1996

Number of
patients
enrolled

Number of
evaluable
patients

Reported
success
rate

Prophylactic
fluconazole
400 mg qd

25

234

96%1,2

No prophylactic
antifungal agent

24

Antifungal
agents

Mortality

Quality
score

30%
NR3

Fluconazole
400 mg, then
200 mg qd
Amphotericin B
1–1.5 mg/kg qod
1
5-Flucytosine
2.5 g tid

ITT
analysis

APACHE
II
scoring?
13

4

204

65%1,2

50%

13

84

25%5,6

63%

21

NR

NR
94

56%5,6

1
33%

20

1 Patients who failed therapy were those who developed Candida peritonitis. Success rates were 83% in the fluconazole
group and 65% in the placebo group if any candidal infection was considered a treatment failure.
2 The difference between the groups was statistically significant (p
5 0.02), in favor of the fluconazole group. The difference between groups was not statistically significant for the development of any candidal infection.
3 No data were provided, but the result of the ITT analysis was stated to confirm the significant difference between the
groups with respect to the development of Candida peritonitis.
4 The values represent the numbers of patients enrolled because of Candida peritonitis. A total of 36 patients were
enrolled in each group because of any type of candidal infection.
5 Success rates are based only on patients reported as clinically cured of
Candida peritonitis. Additional patients with
Candida peritonitis were considered improved, and could have been considered successfully treated, but their numbers
were not reported.
6 Success rates in all treated patients, not just those with
Candida peritonitis, were 67% in the fluconazole group and
69% in the amphotericin B plus 5-flucytosine group.
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al. [126] undertook a prospective randomized
controlled trial of empiric fluconazole therapy
to prevent the development of invasive intraabdominal candidal infections in higher-risk
patients. The study population was restricted
to critically ill patients with recurrent gastrointestinal perforations or other postoperative infections. Candidal peritonitis developed in
only one of the 23 clinically evaluable patients
treated with fluconazole, but in seven of the 20
clinically evaluable patients who received a
placebo. This difference was statistically significant. Overall, 30% of the patients randomized to empiric therapy with fluconazole died,
as opposed to 50% of those in the placebo
group. Although this difference was not statistically significant, four of the 10 deaths in the
latter group were directly attributed to complications of Candida peritonitis (Table 16).
There is some controversy regarding the antifungal agent of choice for patients with conTABLE 17. GUIDELINES

FOR

firmed intra-abdominal candidal infections.
The efficacy of fluconazole for the treatment of
these infections was fortuitously demonstrated
in the data of Eggiman et al. [126], since 40%
of the patients who received fluconazole already had a candidal infection, as evidenced by
isolation of Candida from cultures of peritoneal
fluid obtained at the time of study entry.
Nonetheless, another trial questioned the use
of fluconazole for the treatment of candidal
peritonitis. This prospective randomized controlled trial compared fluconazole with amphotericin B and 5-flucytosine for the treatment
of critically ill patients with candidiasis from
any source. Seventeen of the 72 evaluable patients in this trial had Candida peritonitis. Two
of the eight patients (25%) treated with fluconazole were cured, as compared to five of the
nine (56%) treated with amphotericin B and 5flucytosine (Table 16). These results did not
reach statistical significance because of the

ANTIMICROBIAL THERAPY

FOR THE

HIGHER -RISK PATIENT

1. In patients with intra-abdominal infections, treatment failure and death is associated with patient-related risk
factors such as advanced age, poor nutritional status, a low serum albumin, and preexisting medical
conditions, especially cardiovascular disease. A higher APACHE II score is the most consistently recognized
risk factor for both death and treatment failure (Level 1).
2. Disease- and treatment-related risk factors, including a nosocomial origin of infection, the presence of resistant
pathogens, and the lack of adequate source control, are associated with treatment failure and death (Level 2).
3. Patients at higher risk for failure (particularly from non–community-acquired organisms) should be treated
with an antimicrobial regimen having a broader spectrum of coverage of gram-negative aerobic/facultative
anaerobic organisms (Level 3):
Single agents:
Imipenem/cilastatin
Meropenem
Piperacillin-tazobactam
Combination regimens:
Aminoglycoside plus antianaerobe
Aztreonam plus clindamycin
Ciprofloxacin plus metronidazole
Third/fourth generation cephalosporin plus antianaerobe
4. Routine addition of an aminoglycoside to other effective gram-negative agents such as imipenem/cilastatin,
piperacillin/tazobactam, or third- or fourth-generation cephalosporins, is not recommended (Level 2).
5. High-risk patients likely to fail due to Enterococcus, such as those of advanced age, with higher APACHE II
scores, a colonic or small bowel source of infection, a postoperative infection, or a nosocomial origin of
infection, may benefit from the use of a regimen covering this organism (Level 3).
6. Addition of empiric antifungal therapy with fluconazole is reasonable for patients with postoperative intraabdominal infections at high risk for candidiasis (Level 2). For patients with established Candida peritonitis,
antifungal therapy with amphotericin B may be preferable to use of fluconazole, but the choice of therapy
must be influenced by the risk of toxicity in a given patient (Level 3).
7. Patients with tertiary peritonitis are likely to harbor difficult to eradicate organisms, such as coagulase-negative
staphylococci, enterococci (including vancomycin resistant enterococci), multiply-resistant gram-negative bacilli,
and yeast (Level 2). Empiric therapy should be directed at organisms likely to be present based on the
patient’s history of previous antimicrobial therapy and local patterns of infectious organisms and resistance.
Empiric therapy should be modified according to definitive culture results (Level 3).
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small number of patients in this subset analysis, but they raised some concern with regard
to the efficacy of fluconazole in a particularly
severely ill population of patients with intraabdominal candidal infections.
Overall, based on this limited evidence, the
Committee recommends empiric use of fluconazole in patients who are at high risk for
failure due to candidal infections in the abdomen. Examples of such patients include
those with recurrent gastrointestinal perforations or anastomotic leaks, and those who develop or have persistent infections after operative management of acute pancreatitis. For
critically ill patients with established candidal
peritonitis, there is a suggestion that amphotericin B may be preferable to fluconazole.
However, additional considerations, particularly the risks of toxicity in a given patient,
must also be factored into the decision to select
a specific antifungal agent.
Tertiary peritonitis. Patients who have persistent intra-abdominal infections after multiple
therapeutic attempts are described as having
tertiary peritonitis. There are relatively few
data to guide treatment decisions in this group
of patients. Typically, these patients are infected with resistant organisms such as coagulase–negative Staphylococcus, enterococci, including those resistant to vancomycin,
multiply resistant gram-negative bacilli, and
fungal organisms, including many that are resistant to fluconazole [128,129]. Open abdominal techniques have been used in some of these
patients as a means of achieving source control,
but the efficacy of such methods has not been
proved definitively.
The consensus of the Committee is that antimicrobial therapy needs to be individualized
for patients with tertiary peritonitis. Empiric
antimicrobial therapy should be directed at the
nosocomial organisms likely to be causing the
infection, based on individual and institutional
experience. The choice of agents should also reflect the resistance patterns of likely pathogens,
the patient’s history of prior antimicrobial exposure, and the results of the Gram stain of infected peritoneal fluid, when available. Empiric
therapy is adjusted subsequently according to
the final culture results.
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Patients suffering from tertiary peritonitis
have an overwhelming failure of host defense
mechanisms [128–130]. Treatment failure is
common, and many of these patients eventually succumb to the effects of multiple organ
failure, whether or not the intra-abdominal infection has been controlled. This has led some to
speculate that antimicrobial therapy should not
be used in patients with tertiary peritonitis.
However, in the absence of data establishing a
benefit of not treating pathogenic microorganisms, the Committee concurs with the opinion of
Solomkin [130] that specific antimicrobial therapy is warranted for these very challenging
patients. Guidelines for the identification and
treatment of higher-risk patients with intra-abdominal infections are listed in Table 17.
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APPENDIX: EXPLANATIONS OF HEADINGS
AND ABBREVIATIONS FOUND IN TABLES 3–8
Headings
Antimicrobial agents or antifungal agents. Only the initial doses of antimicrobials are indicated.
If aminoglycoside dosing was subsequently modified according to monitoring of serum aminoglycoside concentrations, this is indicated in the footnotes. Dosing modifications of other agents
are also indicated in the footnotes.
Number of patients enrolled. These numbers represent all patients randomized to study treatment. If patients were enrolled for diagnoses other than intra-abdominal infections, this is indicated in the footnotes. The inclusions of patients less than 14 years of age are indicated in the
footnotes.
Number of evaluable patients. These numbers represent the number of clinically evaluable patients actually used in determining success rates. Inclusions of patients in the clinically evaluable population who did not have complicated intra-abdominal infections, that is, those who
did not undergo primary source control procedures, are indicated in the footnotes.
Reported success rate. Success rates are based on clinically evaluable patients with intra-abdominal infections. In studies reporting treatment results other than success or failure, success
rates were calculated after counting all patients classified as “improved” as successfully treated,
and excluding patients classified as having indeterminate outcomes. If several success rates were
reported, the rates indicated are those determined at the latest time point for which follow-up
was complete. If the investigators did not report an overall success rate, it was calculated as best
as possible using the data provided in the publication. Except for these exceptions, the success
rates reported by the investigators were accepted as final, regardless of the criteria used to define success and failure.
Percentage of patients with sSSI. If information was provided in the publication, the percentages
of patients who developed sSSI were determined, whether or not these infections were considered to represent a failure of therapy.
Success rate excluding isolated sSSI. The reported success rates were recalculated after counting
patients who failed therapy only because of isolated sSSI as successfully treated. N/A indicates
that the calculation could not be performed because the number of patients who failed therapy
because of isolated sSSI could not be determined.
ITT analysis. Only analyses reported by the authors are included.
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Mortality. These values were based on the clinically evaluable populations unless otherwise
indicated.
Percentage of patients with hollow viscus injury and percentage of patients with appendicitis. These
values were based on the clinically evaluable populations unless otherwise indicated.
Quality score. These values were determined according to the procedure of Jadad et al. [22].
N/A is indicated for class II studies, which were not graded.
APACHE II scoring? “Yes” indicates that scoring was performed. If mean APACHE II scores
were reported, they are included in the table.
Specified treatment duration. The duration of treatment specified by the protocol.
Duration of antimicrobial therapy. The average length of time patients actually received antimicrobial therapy.
Complicated infection per IDSA criteria? “Yes” indicates that the authors used the criteria of
Solomkin et al. [6] or similar criteria to determine enrollment and inclusions of patients in the
clinically evaluable populations. “No” indicates that patients who did not have intra-abdominal
infections or did not undergo primary source control procedures were considered clinically
evaluable, or that patients with negative peritoneal cultures were included in the clinically evaluable populations. “Probably not” indicates that all patients had intra-abdominal infections and
positive peritoneal cultures, but that some patients may have had localized infections or intraabdominal contamination not requiring therapeutic antimicrobial therapy. Examples of such patients include those with localized, non-perforated appendicitis and those with recent gastroduodenal or traumatic enteric perforations.
Abbreviations
ITT
NR
N/A
IDSA
NYHA
sSSI

Intention-to-treat
Not reported
Not applicable
Infectious Disease Society of America
New York Heart Association
Superficial surgical site infection

